Drug, bio-affecting and body treating compositions inventions 04/08

20080096792 - Peptide and a derivative thereof promoting cell adhesion and spreading: The present invention relates to a peptide promoting cell adhesion and spreading, fragments, and derivatives thereof, more particularly, integrin-α3β1-dependent peptide in human laminin-5 α3 chain LG3 domain, mediating integrin α3β1 binding and cell adhesion and spreading, fragments and derivatives thereof. The inventive peptide, fragments and derivatives thereof can be used... Agent: Intellectual Property / Technology Law

20080096798 - Method for promoting hard tissue formation: Formulations and methods to promote biological processes to form or regenerate new hard tissues such as bones, cartilage, and/or dental tissues are disclosed. The formulation comprising two proteins is administered to enhance biological activities of a hard tissue growth and differentiation factor characterized by specific and selective upregulation and/or extension... Agent: Bozicevic, Field & Francis LLP

20080096805 - Nitric oxide-blocked cross-linked tetrameric hemoglobin: The present invention includes compositions containing carboxamidomethylated cross-linked hemoglobin where the cysteine moiety of the hemoglobin includes a thiol protecting group and where the hemoglobin has a reduced ability to bind with nitric oxide. Preferably, the hemoglobin is deoxygenated, endotoxin free, and stroma free. The present invention also includes method... Agent: Wilson Sonsini Goodrich & Rosati

20080096810 - Cab molecules: The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy.... Agent: Victoria L. Boyd Genencor International

20080096809 - Diastereomeric peptides useful as inhibitors of membrane protein assembly: The present invention relates to membrane binding diastereomeric peptides comprising amino acid sequences corresponding to a fragment of a transmembrane proteins, wherein at least two amino acid residues of the diastereomeric peptides being in a D-isomer configuration. The diastereomeric peptides are useful in inhibiting fusion membrane protein events, including specifically... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080096811 - Selective vpac2 receptor peptide agonists: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.... Agent: Eli Lilly & Company

20080096833 - Polytpeptide specific to liver cancer, polynucleotide coding for the polypeptide, and rna molecule inhibiting expression of the polypeptide: There are provided a polypeptide specific to liver cancer, a polynucleotide coding for the polypeptide, and an RNA molecule suppressing the expression of the polypeptide. The present invention is particularly intended for a polypeptide comprising the amino acid sequence of SEQ ID NO: 1; a polypeptide having at least 80%... Agent: Reed Smith LLP

20080096797 - Calcium phosphate delivery vehicles for osteoinductive proteins: A composition for delivery of osteogenic proteins is disclosed. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080096793 - Class iii slrp for the treatment of cancer: There is provided the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the prevention and/or treatment of cancer. Such medicaments may be used in the treatment of tumours, including avascular tumours. Suitable agents to be used may preferably include the class... Agent: Michael Best & Friedrich LLP

20080096795 - Novel antiangiogenic peptide agents and their therapeutic and diagnostic use: The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy... Agent: Sutherland Asbill & Brennan LLP

20080096794 - Peptide mixture from peptides having a molecular weight of from 1000 to 5000 dalton: The invention relates to the use of a peptide mixture comprising peptides with a molecular weight from 1000 to 5000 Daltons for the prevention and/or treatment of tumour diseases, of diseases which are associated with a development disorder of the immune system, of diseases of the immune system, of autoimmune... Agent: Bacon & Thomas, PLLC

20080096796 - Peptides that stimulate cell survival and axon regeneration: Peptides which consist of or comprise the tetrameric peptide structural unit: Xaa-Xaa-Xaa-Xaa (SEQ.ID.NO.: 1) in which Xaa at position 1 represents Glu or Asp, Xaa at position 2 represents any amino acid, Xaa at position 3 represents any amino acid and Xaa at position 4 represents Glu or Asp, each... Agent: Haynes And Boone, LLP

20080096801 - Compositions and methods for the prevention and control of insulin-induced hypoglycemia: Pharmaceutical composition comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia.... Agent: Townsend And Townsend And Crew, LLP

20080096799 - Compounds for and methods of treating insulin resistance and inflammation: Novel compounds, compositions comprising compounds, and methods for preparing and using compounds are described herein. Methods of treating or ameliorating various conditions, including insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia, manifestations of Syndrome X, congestive heart failure, inflammatory disease of the cardiovascular system, atherosclerosis,... Agent: Kirton And Mcconkie

20080096800 - Rapid mucosal gel or film insulin compositions: Gel, powder, suspension, emulsions or film formulations for systemic delivery of insulin with improved stability and rapid onset of action are described herein. The formulations are preferably absorbed to a mucosal surface, most preferably via buccal or sublingual administration, although rectal, vaginal, nasal or ocular administration is possible. The formulations... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080096802 - Combination therapy comprising glucose reabsorption inhibitors and ppar modulators: Combination therapy comprising PPAR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20080096803 - Carboxymethylated cross-linked tetrameric hemoglobin: The present invention includes compositions containing carboxymethylated cross-linked hemoglobin where the cysteine moiety of the hemoglobin includes thiol protecting group and where the hemoglobin is incapable of binding with the nitric oxide. Preferably, the hemoglobin is deoxygenated, endotoxin free, and stroma free. The present invention also includes method of preparation,... Agent: Wilson Sonsini Goodrich & Rosati

20080096804 - Pure amino acid chelate complexes and uses thereof: A two-stage method of preparing essentially pure amino acid chelates, wherein the first stage comprises contacting a metal ion from a metal oxide or hydroxide with an amino acid thereby producing a metal hydroxyl amino acetate. The second stage comprises contacting the metal hydroxyl amino acetate from the first stage,... Agent: Fasken Martineau Dumoulin LLP

20080096806 - Compositions and methods for inhibiting microbial adhesion: The present invention provides compositions and methods for treating or preventing microbial infections.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080096807 - Cyclic vasoactive intestinal peptide receptor-2 agonists: e

20080096808 - Use of rapamycin to inhibit response and induce tolerance to gene therapy vector and encoded transgene products: Disclosed are methods for transient co-administration of rapamycin together with a gene therapy vector encoding a transgene. The present invention is directed to inhibiting the immune response of a host to the administered gene therapy vector and encoded trans gene product, thus allowing persistent trans gene expression and repeated administration... Agent: Genzyme Corporation Legal Department

20080096819 - Amino acid substituted molecules: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also... Agent: Seed Intellectual Property Law Group PLLC

20080096821 - Cytostatin ii: The invention relates to cytostatin II growth modulatory polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080096813 - Generation of potent dominant negative transcriptional inhibitors: The present invention provides methods and compositions for regulating gene expression using transcription factors linked to proteins that localize to the transcriptional machinery.... Agent: Townsend And Townsend And Crew, LLP

20080096817 - Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tbeta4), analogues, isoforms and other derivatives: Eye degradation such as may be associated with dry eye syndrome is inhibited or reversed by administration of an actin-sequestering peptide such as Thymosin β4, an isoform of Thymosin β4 or oxidized Thymosin β4.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080096814 - Orally administered peptides synergize statin activity: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention... Agent: Beyer Weaver LLP

20080096815 - Orally administered peptides synergize statin activity: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention... Agent: Beyer Weaver LLP

20080096816 - Orally administered peptides synergize statin activity: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention... Agent: Beyer Weaver LLP

20080096818 - Prevention and treatment of amyloidogenic disease: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease.... Agent: Townsend And Townsend And Crew, LLP

20080096820 - Prodomain modulators of adam 10: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080096822 - Use of the neurotoxic component of a botulinum toxin: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.... Agent: Allergan, Inc.

20080096812 - Water-soluble elastin, process for producing same, and food and medicine containing same: A low-molecular-weight water-soluble elastin having a molecular weight of about 10,000 to 30,000 and a high-molecular-weight water-soluble elastin having a molecular weight of about 30,000 to 300,000 are provided, 79% to 84% of the constituent amino acids of the elastin comprising proline, glycine, alanine, and valine, 2% to 3% comprising... Agent: Sughrue Mion, PLLC

20080096823 - Neurotensin receptor agonists and opioid receptor agonists: This document provides methods and materials for treating pain. For example, this document provides methods that involve administering a neurotensin receptor (NTR) agonist and an opioid receptor agonist to a mammal (e.g., a human). Compositions containing an NTR agonist in combination with an opioid receptor agonist also are provided.... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-1118

20080096824 - Ku-70-derived bax-suppressing peptides and use thereof for the protection of damaged cells: A method of protecting cells from cell death comprising the step of supplying to the cell an effective amount of a Bax-inhibiting peptide is disclosed.... Agent: Quarles & Brady LLP

20080096825 - Preparation and use of phlorizin compositions: The present invention concerns the isolation of phlorizin from plants of the genus Lithocarpus, phlorizin-containing compositions and their uses.... Agent: Heller Ehrman LLP

20080096826 - Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments: The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from... Agent: Swanson & Bratschun, L.L.C.

20080096827 - Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments: The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from... Agent: Swanson & Bratschun, L.L.C.

20080096828 - 7-quinolyl ketolide antibacterial agents: e

20080096830 - Anti-inflammatory macrolide conjugates: wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, D represents a dibenzo[e,h]azulene subunit with anti-inflammatory, analgesic and/or antipyretic activity and L represents a linking group covalently linking M and D; (b) to their pharmacologically acceptable salts, prodrugs and solvates,... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080096829 - Macrolone compounds: e

20080096832 - Method for improving the pharmacokinetics of an nnrti: An improved method for using a NNRTI in the treatment of HIV-1 infection, comprising administering to a human, needing treatment for HIV-1 infection, a therapeutically effective amount of said NNRTI or a pharmaceutically acceptable salt thereof, and an amount of an inhibitor of the cytochromes P450 that is sufficient to... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080096831 - Stabilized azithromycin composition: A stabilized azithromycin composition comprising azithromycin monohydrate, and about 5 to about 15 weight percent, based on the total weight of the composition, of water. The present inventors have unexpectedly determined that a certain amount of water is necessary to stabilize a pharmaceutical composition comprising azithromycin monohydrate. In addition, the... Agent: Sandoz Inc

20080096834 - Anti-tumor activity of ea-4-peptide of pro-igf-i: Compositions of pro-IFG-I E-peptides for the treatment and amelioration of tumor-producing diseases, and methods for their utilization.... Agent: Mccarter & English LLP Cityplace I

20080096837 - Defective sindbis viral vectors: Disclosed herein are new defective Sindbis viral vectors made from wild type Ar-339 Sindbis virus, with differences in replicase and envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for... Agent: Darby & Darby P.C.

20080096838 - Guanosine rich oligonucleotides and methods of inducing apoptosis in tumor cells: Presently described is a guanosine-rich polynucleotide molecule with therapeutic utility for treating or preventing the growth of cancerous cells. In addition, a method of retarding cell cycle progression and inducing apoptosis in tumor cells using synthetic oligonucleotides is also described.... Agent: Mccarter & English, LLP Basil S. Krikelis

20080096835 - Inhibitory oligonucleotides targeted to bcl-2: Inhibitory oligonucleotides are disclosed which are targeted to three specific target regions and subsequences of the target regions found on nucleic acids encoding Bcl-2. These inhibitory oligonucleotides are generally of from about 8 to about 50 nucleotides in length. Specific preferred oligonucleotides are disclosed. The oligonucleotides of the invention may... Agent: Kenyon & Kenyon LLP

20080096840 - Kinase supressor of ras inactivation for therapy of ras mediated tumorigenesis: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid... Agent: Klauber & Jackson

20080096836 - Screening method: The invention relates to methods for the identification of novel receptors and/or novel ligands. The invention is based on the concept that parasites have developed a number of biologically active compounds in their saliva to cope with the defense mechanisms of the host organisms on which they feed and to... Agent: Klauber & Jackson

20080096839 - Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same: The present invention relates to RNA interference mediated inhibition of Hepatitis B virus (HBV) by short interfering RNA (siRNA) molecules. Specially, siRNAs of the present invention which are double-stranded RNAs concern directing the sequence-specific degradation of viral RNA in mammalian cells. Disclosed is a DNA vector encoding the RNA molecules... Agent: Sughrue Mion, PLLC

20080096841 - Treatment and prevention of heat shock protein-associated diseases and conditions: The invention provides methods of treating and preventing heat shock protein-associated diseases and conditions.... Agent: Clark & Elbing LLP

20080096842 - Preventive/remedy for obesity: The present invention relates to raw materials for pharmaceuticals and the like, wherein the raw materials can be effective in preventing and remedying various lifestyle-related diseases such as obesity and hyperlipidemia, safe, and applicable in wide areas; and the present invention also relates to a preventive/remedy for obesity, an agent... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080096843 - Substituted isoxazoles as fungicides: The present invention provides compounds of formula I: (I) along with methods of making the same, compositions thereof, and methods of use thereof, particularly methods of use as fungicides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080096844 - Novel inhibitors of chymase: e

20080096845 - Sphingomyelin therapy of autoimmune disease: Autoimmune disease therapy in a patient treated with apoptosis-inducing agents is enhanced by co-administration of sphingomyelin. The combination most likely enhances an autoimmune disease cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. In alternative embodiments,... Agent: Faegre & Benson LLP Patent Docketing

20080096846 - Arene ruthenium (ll) compounds and their use in cancer therapy: A ruthenium (II) compound of formula (I): or a solvate on prodrug thereof, wherein: R1, R1, R3, R4, R5 and R6 are independently selected from H, C1-7 alkyl, C5-20 aryl, C3-20 heterocyclyl, halo, ester, amido, acyl, sulfo, sulfonamido, ether, thioether, azo, amino, or R1 and R2 together with the ring... Agent: Curatolo Sidoti Co., Lpa

20080096847 - Composition and method for inducing or restoring locomotor functions in an animal: The present invention relates to the field of neuropathological disorders involving impaired locomotor functions. More specifically, the present invention relates to a composition and method for inducing and restoring locomotor functions, such as basic walking movements in the lower extremities of chronic spinal cord injured animals, such as paraplegic or... Agent: Baker & Hostetler LLP

20080096849 - Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives: A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication... Agent: Edwards Angell Palmer & Dodge LLP

20080096848 - Substituted n-aryl-9-oxo-9h-fluorene-1-carboxamides and analogs as activators of caspases and inducers of apoptosis: The present invention is directed to substituted N-aryl-9-oxo-9H-fluorene-1-carboxamides and analogs thereof, represented by the general Formula I: (I) wherein R1-R8, X and Ar are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080096850 - Methods for inhibiting the production of tsst-1: Methods for inhibiting the production of TSST-1 from Gram positive bacteria are disclosed. The methods comprise exposing the Gram positive bacteria to compounds capable of inhibiting the production of TSST-1 from the Gram positive bacteria.... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20080096851 - (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses: This invention discloses (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall

20080096852 - Use of oculosurface selective glucocorticoid in the treatment of dry eye: Topical ophthalmic compositions and methods for treating dry eye are described. The compositions and methods of the invention are based on the finding that the oculosurface selective properties of the glucocorticoid rimexolone make this anti-inflammatory agent particularly well-suited for treating dry eye. As a result of the limited ability of... Agent: Alcon

20080096854 - Composition and method for treating or preventing gastrointestinal cancer: The present invention provides novel compositions and methods for repair and regeneration of tissues or organs of the body, especially mucosa in the gastrointestinal tract. The composition can be used as a pharmaceutical or nutraceutical to treat or prevent gastrointestinal cancer such as colorectal carcinoma, stomach cancer and esophagus cancer.... Agent: Wilson Sonsini Goodrich & Rosati

20080096853 - Edible compositions comprising a primary lipid, a co-lipid, a lipohilic physiologically active ingredient and water, and their preparation: A composition comprising: a) a primary lipid component obtainable as the reaction product of one or more carboxylic acids with at least one of glycerol and propylene glycol; b) a co-lipid component selected from at least one of phosphorus-containing lipids and hydroxylated carboxylic acid esters of mono- and di-glycerides; c)... Agent: Unilever Intellectual Property Group

20080096855 - Process for obtaining norelgestromin in different relations of isomers e and z: c

20080096856 - Antibiotic compound: Fermentation of a nutrient medium with a Nocardia spp. yields a novel broad spectrum antibiotic compound of structural formula (I) or a pharmaceutically acceptable salt, ester, enantiomer, diasteriomer or mixture.... Agent: Merck And Co., Inc

20080096857 - Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied hydrophobic green porphyrins: The present method involves the photodynamic treatment of hyperactive gland disorders. The method involves the topical administration of a photosensitizer composition comprising hydrophobic and/or lipophilic green porphyrins such as lemuteporfin, polyethylene glycol and skin penetration enhancers such as oleyl alcohol and TRANSCUTOL™ to affected skin and subsequent exposure of that... Agent: Morrison & Foerster LLP

20080096858 - Method of stabilizing disordered cefovecin sodium salt: A method of stabilizing pharmaceutical compositions containing cefovecin sodium salt which is in an amorphous or other disordered state is disclosed.... Agent: Pharmacia & Upjohn

20080096859 - Compositions and methods for treating ophthalmic diseases: This invention relates to CXCR4 inhibitors and their use in treating and/or preventing a variety of angiogenic, microvascular and ocular disorders including primary indications for diabetic retinopathy, macular degeneration (such as wet or neovascular age-related macular degeneration (AMD) and dry or atrophic AMD), macular edema, and secondary indications for inhibiting... Agent: Merck And Co., Inc

20080096860 - Pyrimidine sulphonamide derivatives as chemokine receptor modulators: A compound of formula (1), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.... Agent: Fish & Richardson P.C.

20080096861 - Chemical compounds: The present invention provides compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 of a target cell.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080096863 - Stable pharmaceutical compositions of calcium channel blocker and an ace inhibitor: The present invention relates to a stable pharmaceutical composition of a combination of amlodipine and an ACE inhibitor; wherein the two active ingredients are not physically separated and the composition has a pH of more than 6.0. It also relates to a process for preparation, and a method for using... Agent: Darby & Darby P.C.

20080096864 - Treatment of gastrointestinal stromal tumors with imatinib and midostaurin: The present invention relates to the use of a combination comprising (a) imatinib or a pharmaceutically acceptable salt thereof and midostaurin or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of gastrointestinal stromal tumors, e.g. imatinib-resistant gastro-intestinal stromal tumors.... Agent: Novartis Corporate Intellectual Property

20080096865 - Method for treating neovascularization: The present invention describes an improved photodynamic treatment to treat subfoveal choroidal neovascularization (CNV).... Agent: Novartis Corporate Intellectual Property

20080096866 - Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductace inhibitor and antihypertensive agent, and process for preparing same: A complex formulation for oral administration comprising a sustained release formulation of an HMG-CoA reductase inhibitor and a film layer for rapid release of an anti-hypertensive agent, the film layer being coated on the sustained release formulation, can achieve improved therapeutic effects of the anti-hypertensive agent by promptly releasing it,... Agent: Sughrue Mion, PLLC

20080096862 - Lactam compounds and pharmaceutical use thereof: An agent for increasing the sugar-transporting capacity and an agent for preventing and/or treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which contains a lactam compound or a pharmaceutically acceptable salt thereof as the active ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080096867 - Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductace inhibitor and antihypertensive agent, and process for preparing same:

20080096868 - 1,4 substituted pyrazolopyrimidines as kinase inhibitors: pharmaceuticals comprising a 1,4-substituted pyrazolopyrimidine compound, the use of a 1,4-substituted pyrazolopyrimidine compound in the treatment or the use thereof in the manufacture of a pharmaceutical formulation for the treatment of a disease that depends on inadequate activity of a protein kinase, methods of treatment comprising administering a 1,4-substituted pyrazolopyrimidine... Agent: Novartis Institutes For Biomedical Research, Inc.

20080096869 - Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors:  wherein said C6-12cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C1-4alkyl, C1-4alkyloxy, halo or hydroxy; Q represents Het1 or Ar2 wherein said C3-8cycloalkyl, Het1 or Ar2 are optionally substituted with one or where possible... Agent: Philip S. Johnson Johnson & Johnson

20080096870 - Methods and materials for treating mental illness: The subject invention pertains to methods of treating mental illnesses or conditions characterized by a decreased function of NMDA receptors and/or excessively enhanced glutamate release and activity of non-NMDA receptors (AMPA and/or kainate). Specifically disclosed are methods utilizing BrPhe, or isomers of analogs thereof, for treating or preventing mental illness... Agent: Beusse Wolter Sanks Mora & Maire

20080096872 - Composition for treatment of pain specification: A method for the treatment of pain and/or inflammation in a subject by the administration of N-acetyl-cysteine (NAC) or derivative thereof and a pain and/or anti-inflammatory medication. The pain or anti-inflammatory medication is metabolized by the action of the cytochrome p450 system. The pain medication includes N-methyl-D-aspartate (NMDA) receptor antagonist(s).... Agent: Venable LLP

20080096871 - Olanzapine pamoate dihydrate: The present invention relates olanzapine pamoate dihydrate, pharmaceutical compositions thereof and use in treating certain mental disorders, such as schizophrenia.... Agent: Eli Lilly & Company

20080096873 - New compounds: The present invention relates to substituted bis-arylsulfonamide and arylsulfonamide compounds of the general formula (I) or the formula (II), which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.... Agent: Fish & Richardson PC

20080096874 - Oxadiazole derivative as dgat inhibitors: Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an... Agent: Morgan Lewis & Bockius LLP

20080096875 - Thiourea compounds: m

20080096876 - Phenylalkynes: Substituted phenylalkynes of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.... Agent: Philip S. Johnson Johnson & Johnson

20080096877 - Indole compound: b

20080096878 - Bicyclic anilide spirolactam cgrp receptor antagonists: The present invention is directed to compounds of Formula (I): (where variables A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such... Agent: Merck And Co., Inc

20080096879 - Synthesis of fr901464 and analogs with antitumor activity: The present invention provides novel analogs of FR901464, as well as an improved methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associated with dysfunctional RNA splicing.... Agent: Foley And Lardner LLP Suite 500

20080096880 - Novel use of imidazotriazinones: The invention relates to novel uses of imidazo[1,2,4]triazinones for producing a medicament for the treatment and/or prophylaxis of coronary cardiopathy, heart failure, pulmonary hypertension, bladder complaints, prostatic hyperplasia, nitrate-induced tolerance, or diseases of the eye, such as glaucoma, for the treatment or prophylaxis of central, retinal or posterior ciliary artery... Agent: Bayer Health Care LLC

20080096881 - Quinazoline derivatives: The invention concerns quinazoline derivatives of Formula (I): wherein each of R1, X1, R2, R3, R5, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080096882 - Dihydrothienopyrimidines for the treatment of inflammatory diseases: e

20080096883 - Trifluoromethyl substituted benzamides as kinase inhibitors: The invention relates to trifluoromethyl substituted benzamide compounds of the formula (I), pharmaceuticals comprising these compounds, their use as or for the manufacture of pharmaceuticals, particularly as inhibitors of protein kinases and/or the treatment of a condition, disorder or disease state mediated by a protein kinase activity and/or a proliferative... Agent: Novartis Institutes For Biomedical Research, Inc.

20080096884 - 4-aminoquinoline-3-carboxamide derivatives as pde4 inhibitors: e

20080096887 - Benzene, pyridine, and pyridazine derivatives: wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080096886 - Process for the manufacture of 3-hydroxy-n-alkyl-1-cycloalkyl-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide and its related analogues: The process includes reacting an amine R2NH2 with a compound of formula II in a solution of metal hydroxide in water to give a compound of formula III. Subsequent reaction of the compound of formula III with an acid chloride formation reagent in an inert solvent gives compounds of formula... Agent: Ivor M Hughes

20080096885 - Quinoline derivatives as neurokinin receptor antagonists: The present invention relates to substituted quinoline-4-carboxylic acid hydrazides defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors.... Agent: Merck And Co., Inc

20080096888 - Novel compounds as opioid receptor modulators: e

20080096889 - Histone deacetylases inhibitors: where R1 is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R3 is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of... Agent: Mccormick, Paulding & Huber LLP

20080096890 - Highly selective norepinephrine reuptake inhibitors and methods of using the same: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about... Agent: Marshall O'toole Gerstein Murray & Borun 6300 Sears Tower

20080096891 - Triazine derivatives, their preparation and therapeutic application thereof: t

20080096892 - C-kit modulators and methods of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellu-lar activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Even more specifically, the invention provides compounds for modulating c-Kit kinase activity and methods of treating diseases mediated by c-Kit activity utilizing the compounds and... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20080096893 - Aminopterin dosage forms: Embodiments of the present invention provide dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Within certain embodiments, the present invention provides a method for treating an inflammatory... Agent: Syntrix Biosystems, Inc.

20080096895 - Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors: b

20080096894 - Anti-bacterial compounds: Compounds of formula (I), or salts or solvates thereof, in vitro as inhibitors of growth of Gram-positive bacteria, where A is selected from formula (a).... Agent: Michael Best & Friedrich LLP

20080096896 - Cyclic amide & ester pyrazinoylganidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080096897 - 5-(1,1'biphenyl)-4-yl-5-(4-(4-aminoacylphenyl)-piperazin)-1-yl-pyrimidine-2,4,6,-trione derivatives, as inhibitors of zinc metallondopeptidases, their preparation and use: New Pyrimidinetrione derivatives represented by formula (I), wherein R1 and R2 are defined in the description, composition thereof, and methods of preparation are described. The compounds are useful in the treatment of disease involving metalloproteinases.... Agent: Jacobson Holman PLLC

20080096898 - Organic compounds: in free or salt form, wherein Ar, R1, R2, R3, X and T have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergic condition such as an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain the compounds... Agent: Novartis Institutes For Biomedical Research, Inc.

20080096900 - Methods for treating atherosclerosis: The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.... Agent: Amgen Inc.

20080096899 - N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof: The present invention relates to a novel N-phenyl-2-pyrimidine-amine derivative represented by the above formula (1) and its salt showing a superior effect on cancer in warm-blooded animals, such as lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder... Agent: Edwards Angell Palmer & Dodge LLP

20080096901 - Aminotriazole compounds useful as inhibitors of protein kinases: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20080096902 - Biomimetic of evodia rutaecarpa fruit extract for amelioration of inflammation: Compositions and methods are provided for reversing and/or inhibiting inflammation, e.g., by inhibiting prostaglandin and/or COX-2 production, using one or more indolequinazoline alkaloids, preferably in combination with butylated hydroxytoluene. The preferred indolequinazoline alkaloids are rutaecarpine, evodiamine, and dehydroevodiamine, which are naturally found in unpurified form in the traditional Chinese medicine... Agent: Maurice M Klee

20080096903 - Sulfamoyl-containing derivatives and uses thereof: Sulfamoyl-containing compounds are disclosed, having utility as inhibitors of disease-related targets, such as Heat Shock Protein 90 (HSP90), and which are useful for treating disorders, e.g., proliferative disorders, including HSP90-mediated disorders. Methods for preparing and using the disclosed compounds are also described.... Agent: Wyeth Patent Law Group

20080096904 - Compositions and methods for treatment and prevention of insulin resistance: Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods... Agent: Beusse Wolter Sanks Mora & Maire

20080096905 - Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido{4,5-d}pyrimidin-2(1h)-one derivatives: s

20080096906 - Aminomethyl-2-imidazoles: —(CR2)m-heteroaryl; each R is selected from the group consisting of hydrogen, lower alkyl and hydroxy; Ar is selected from the group consisting of phenyl, pyrimidin-2-yl, pyrimidin-4-yl and pyridin-3-yl; n is 0, 1 or 2; x is 0, 1, 2 or 3; m is 0 or 1; and to their pharmaceutically... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080096907 - Aryl, pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents: Substituted aryl pyrimidyl compounds responding to formula (I) and their use for the preparation of a medicament for the prevention and/or treatment of a pathology caused by a mycobacteria.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080096908 - Statin derivatives: Statin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for treating and/or preventing several diseases, in particular coronary syndromes, neurodegenerative disorders as well as for reducing cholesterol levels.... Agent: Arent Fox LLP

20080096909 - Apomorphine inhibitors of amyloid-beta (abeta) fibril formation and their use in amyloidosis based disease: Described is a new class of small molecule inhibitors of amyloid β protein (Aβ) aggregation, based on apomorphine. These molecules target the nucleation phase of Aβ self-assembly and interfere effectively with aggregation of Aβ 1-40 into amyloid fibrils in vitro as determined by transmission electron microscopy, Thioflavin T (ThT) fluorescence,... Agent: Law Office Of John K. Pike, PLLC

20080096910 - Rapid release mini-tablets provide analgesia in laboratory animals: Pellets containing an analgesic uniformly dispersed in a lipid carrier such as cholesterol mixed with fatty acid esters, can be used to provide long term pain relief. 5 mg cholesterol-tryglyceride-buprenorphine pellets released the majority of drug in 24-48 hours after implant and provide clinically significant plasma levels of analgesia in... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080096911 - Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity: wherein R1, R2, R3, R4, R5, R6, R7a, R7b, W, G1, G2, a, b, c, d and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds;... Agent: Theravance, Inc.

20080096912 - Indole, azaindole and related heterocyclic pyrrolidine derivatives: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with amido piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the... Agent: Louis J. Wille Bristol-myers Squibb Company

20080096913 - Ppar active compounds: Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.... Agent: Foley & Lardner LLP

20080096914 - Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer: m

20080096915 - Compositions for the treatment of metabolic disorders: Preferred embodiments of the present invention are related to novel therapeutic drugs and drug combinations, and associated methods, for treating and/or preventing complications or otherwise treating disease in patients with hypertension, diabetes, metabolic syndrome, obesity and/or other metabolic disorders.... Agent: Greenberg Traurig, LLP (sv)IPDocketing

20080096916 - Drugs and prodrugs useful the treatment of energy balance in ruminants: The use of a compound of formula (I) an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug, in the manufacture of a medicament for the palliative, prophylactic or curative treatment of negative energy balance in ruminants. The use... Agent: Pfizer Inc.

20080096917 - I-alkynyl-2-aryloxyalkylamides and their use as fungicides: Compounds of the formula wherein the substituents are as defined in the claims, are useful as fungicides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080096918 - Novel cyclic ureas used as inhibitors of metalloproteases: and/or all stereoisomeric forms of the compound of the formula I and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of the formula I, in which R1 to R5 and V1, V2 have the meanings stated in the claims and specification. The inventive... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080096919 - Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same: d

20080096921 - Farnesoid x receptor agonists: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080096920 - Histone deacetylase inhibitors: This invention relates to iminodiacetic acid and diamine hydroxamic acid derivatives, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases, and... Agent: Merck And Co., Inc

20080096922 - Novel sulfonamide derivative: i

20080096923 - Methods for diagnosing and treating diabetic microvascular complications: The present invention relates to a method for treating one or more diabetic microvascular complications in a patient in need of said treatment comprising: (a) diagnosing the severity of at least three different microvascular complications in said patient by calculating a diabetes microvascular complications score with a diabetes microvascular complications... Agent: Eli Lilly & Company

20080096924 - Amorphous composition: To provide an amorphous composition for nasal administration or for administration by adhering to oral mucosa in which absorption property and chemical and physical stabilities of (2R)—N-(1-benzylpiperidin-4-yl)-3-cyclohexylmethylthio-2-[(4R)-3-tert-butoxycarbonylthiazolidin-4-ylcarbonylamino]propanamide which is useful as an N type calcium channel inhibitor are improved. A preparation comprising the amorphous composition of the present invention has... Agent: Sughrue-265550

20080096925 - Novel substituted 4-phenyl-4[h-imidazol-2-yl]-piperidine derivatived and their use as selective non-peptide delta opioid agonists: the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. In particular are claimed compounds according to Formula (I) in which A=B is C═O or SO2, X is a covalent bond, R1 is alkyloxy, alkyloxyalkyl, Ar or... Agent: Woodcock Washburn LLP

20080096926 - Treatment of cognitive impairment using a selective dopamine d1 receptor agonist: Methods of using DAS-431 under conditions where it is administered at a dose that results in improved cognitive performance but without significant side effects are provided. Symptoms can be ameliorated during the period of treatment and, frequently, for substantially longer periods thereafter. In addition, the DAS-431 is provided at a... Agent: Fish & Richardson P.C.

20080096927 - Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events: The invention encompasses a pharmaceutical composition comprising a therapeutically effective amount of a cyclooxygenase-2 selective inhibitor selected from rofecoxib and etoricoxib or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a proton pump inhibitor selected from the group consisting of: omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole, or... Agent: Merck And Co., Inc

20080096928 - Methods for treating hepatitis c: In accordance with the present invention, compounds that inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of the... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20080096929 - Novel use: There is disclosed the use of a compound of formula (I), (I) wherein X, Y, W and Q are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080096931 - Oxadiazole ketone inhibitors of fatty acid amide hydrolase: Certain oxadiazole ketone compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat anxiety, pain, inflammation, sleep disorders, eating... Agent: The Scripps Research Institute

20080096930 - Potentiators of glutamate receptors: The present invention provides compounds of formula (I); pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.... Agent: Eli Lilly & Company

20080096932 - 3-pyridinylethylcarboxamide derivatives as fungicides: e

20080096933 - 4-pyridinylethylcarboxamide derivatives useful as fungicides:

20080096934 - Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor: R6, R7 independently of each other are selected from H, fluorine, C1-C4-alkyl and fluorinated C1-C4-alkyl or together form a moiety (CH2)p with p being 2, 3, 4 or 5; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula... Agent: Wood, Phillips, Katz, Clark & Mortimer

20080096935 - Heterocyclic indanone potentiators of metabotropic glutamate receptors: The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed... Agent: Merck And Co., Inc

20080096936 - Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them: wherein A1, A2, R1, R2, R3, X and n are as defined in the claims, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080096937 - Novel hexafluoroisopropanol derivatives: e

20080096938 - Chemical compounds: The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or S1P receptors.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080096940 - 5-hydroxy-benzothiazole derivatives having beta-2-adrenoreceptor agonist activity: Compounds of formula (I) in free or salt or solvate form, wherein T has the meaning as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the β2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are... Agent: Novartis Institutes For Biomedical Research, Inc.

20080096939 - Process for preparation of pramipexole by chiral chromatography: A novel process for the preparation of S(−)-2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole (pramipexole).... Agent: Wolf Greenfield & Sacks, P.C.

20080096941 - Halogenated benzamide derivatives: A method of treating viral infections by the administration of a halogenated benzamide derivative according to formula (III): in which R1 is a halogen atom, and R2-R6 are independently hydrogen, hydroxyl, C1-C4 alkyl, —C1-C4 alkoxy, acyloxy, nitro, halogen, —C(O)R7 where R7 is —C1-C4 alkyl, or, aromatic including salts and hydrates... Agent: Akerman Senterfitt

20080096942 - Substituted hydroxyethylamines: and the pharmaceutically acceptable salts thereof wherein the variables G, L, A, W, E, R2, R2, R4, R5, RN, and RC are defined herein. These compounds interact with and inhibit the activity of the enzyme beta-secretase. These compounds are therefore useful in treating Alzheimer's disease and other similar diseases. Pharmaceutical... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080096943 - Organic compunds: in free or salt form, wherein T, X, R1, R2, Ra, R3, R4, R5 and U have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergic condition such as an inflammatory or obstructive airways disease. Pharmaceutical compositions that... Agent: Novartis Corporate Intellectual Property

20080096945 - Amorphous and crystalline forms of losartan potassium and process for their preparation: This invention relates to novel amorphous losartan potassium, novel losartan potassium in a crystalline form that is a hydrate, novel crystalline losartan potassium Form IV and solvates thereof, novel crystalline losartan potassium Form V and solvates thereof, to processes for their preparation, to compositions containing them and to their use... Agent: Kenyon & Kenyon LLP

20080096944 - Hydrates of alkaline-earth salts of irbesartan and the preparation thereof: The invention relates to hydrates of pharmaceutically acceptable alkaline-earth salts of irbesartan and to their preparation in an aqueous medium.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080096946 - Process for the preparation of anastrozole: A process for the preparation of anastrozole.... Agent: Wolf Greenfield & Sacks, P.C.

20080096947 - Parenteral forms of administration of imexon and method for the production thereof: The invention relates to intravenously highly compatible imexon injection preparations and processes for their production as well as imexon lyophilisates stable in storage for the production of the injection preparations.... Agent: Foley And Lardner LLP Suite 500

20080096948 - Serotonin antagonist compositions and methods for the local inhibition of pain and inflammation: A method and solution for local inhibition of pain and inflammation by application of a serotonin antagonist, and serotonin antagonist compositions for local delivery.... Agent: Omeros Medical Systems, Inc.

20080096949 - Indazolyl-substituted pyrroline compounds as kinase inhibitors: m

20080096950 - Compounds useful in therapy: and pharmaceutically acceptable salts, solvates (including hydrates) of said compounds and salts, or prodrugs of said compound, or pharmaceutically acceptable salts or solvates of said prodrugs, wherein the substituents are as herein defined, are useful in therapy, for example they may be useful for treating progesterone-mediated conditions such as endometriosis,... Agent: Pfizer Inc.

20080096951 - Carvedilol monocitrate monohydrate: This invention relates to carvedilol monocitrate monohydrate, compositions containing this salt of carvedilol and methods of using this compound to treat hypertension, congestive heart failure and angina.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080096952 - Methods for the treatment of atherosclerosis, using substituted phenethylsulfones: Methods and compositions for the prevention and treatment of all forms of atherosclerosis are described. Administration of compounds such as thalidomide, its analogs, hydrolysis products, metabolites, derivatives and precursors as well as additional compounds capable of inhibiting tumor necrosis factor α (TNF-α) are used in the invention. Also disclosed is... Agent: Jones Day

20080096953 - Vinylogous acid derivatives: t

20080096954 - Novel bicyclic compounds as modulators of androgen receptor function and method:

20080096955 - Histamine-3 receptor antagonists: as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a process of preparation of a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering... Agent: Pfizer Inc

20080096956 - Use of malonomicin and analogs in fungicidal applications: The present invention is related to the use of malonomicin compounds and derivatives in fungicidal applications and to new derivatives of malonomicin.... Agent: Dow Agrosciences LLC

20080096957 - Albumin-binding conjugates comprising a fatty acid and peg: The present invention provides an albumin-binding compound essentially of the following elements: a spacer group, a water-soluble bridging group, a fatty acid chain and an acidic group characterised in that the acidic group is attached to the distal end of the fatty acid chain. The invention also provides an albumin-binding... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080096958 - Antibacterial composition: The object of the present invention is to provide an antibacterial composition which has an improved antibacterial effect and a wider antibacterial spectrum than conventional antibacterial agents and which is highly safe. This object is achieved with an antibacterial composition comprising 9-(3′,7′-dimethyl-2′,6′-octadienyl)-4-hydroxy-7H-furo[3,2-γ][1]benzopyran-7-one and 8-(3′,7′-dimethyl-2,6′-octadienyl)-5-hydroxy-7-methoxy-2H-1-benzopyran-2-one.... Agent: Morgan Lewis & Bockius LLP

20080096959 - Durable biocides and disinfectants: Contemplated compositions and methods include a catechin at a concentration effective to inactivate SARS at least by a factor of 2 log 10 units when the formulation is applied to a surface. Preferably, the catechins are provided as a complex mixture, and most preferably as a near-native catechin preparation from... Agent: Rutan & Tucker, LLP.

20080096960 - Acyloxyalkyl carbamate prodrugs, methods of synthesis and use: The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders... Agent: Dorsey & Whitney LLP

20080096961 - Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma: The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080096962 - Process for the preparation of substituted tetralin and substituted indane derivatives: The present invention relates to novel processes for the preparation of substituted tetralin and substituted indane derivatives. The present invention is further directed to novel processes for the preparation of intermediates in the preparation of the substituted tetralin and substituted indane derivatives.... Agent: Philip S. Johnson Johnson & Johnson

20080096963 - Use of a fatty acid for preparing a topical composition for allaying inflammatory reaction due to vennemous hymenoptera strings: The invention relates to the use of a fatty acid for preparing a composition for allaying inflammatory reactions due to hypenoptera stings.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080096964 - Food fortification with polyunsaturated fatty acids: Coated food products fortified with a polyunsaturated fatty acid, including sweetened food products, and methods for their preparation are provided.... Agent: Sheridan Ross PC

20080096965 - (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators: The invention relates to the use of selected (R)-2-[(halobenzyloxy)benzylamino]-propanamides and the pharmaceutically acceptable salts thereof for the manufacture of medicament, that are selectively active assodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, pain, migraine, periferal diseases, cardiovascular diseases, inflammatory... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080096966 - Ophthalmic compositions containing diglycine: Ophthalmic composition comprising one or more polyglycines selected from the group consisting of diglycine, triglycine, tetraglycine and pentaglycine, or the salts of each thereof and one or more boron buffering compounds. The ophthalmic composition will have an osmolality of from 200 mOsmol/kg to 420 mOsmol/kg.... Agent: Bausch & Lomb Incorporated

20080096967 - Formulations for injection of catecholic butanes, including ndga compounds, into animals: The present invention provides for a composition, kit and method for treatment of diseases, where the composition contains at least one catecholic butane, including NDGA compounds and derivatives, together with a pharmaceutically acceptable carrier that may include solubilizing agents or excipients, where the composition is suitable for injection into animals.... Agent: Panitch Schwarze Belisario & Nadel LLP

20080096968 - Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases: The present invention concerns novel derivatives of 1-phenylalkanecarboxylic acids, pharmaceutical compositions thereof, a process for their preparation and their use for the treatment and/or prevention of neurodegenerative diseases such as Alzheimer' s disease.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080096969 - N alpha-(menthanecarbonyl)amino acid amides and use thereof as physiological cooling active ingredients: e

20080096970 - Stable nateglinide form b compositions: A process for preparing nateglinide Form B comprises dissolving nateglinide in a solvent and adding the solution, at temperatures of 40-45° C., to a hydrocarbon liquid that is at temperatures of 40-45° C. Then, water is added and the mixture is allowed to cool, producing crystals of nateglinide Form B.... Agent: Dr. Reddy's Laboratories, Inc.

20080096971 - Treatment of inflammatory disorders and pain: wherein R1 is CHR4—OR5 or CHR4—SR5, or aryl or heteroaryl optionally substituted with one or more groups R6; R2 is alkyl or is part of a ring with R3; R3 is H, alkyl or CH2 (when forming part of a ring with R2); R4 is H or alkyl or is... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080096972 - Compound formulations of 2-amino-1, 3-propanediol compounds: Pharmaceutical concentrate formulations comprising 2-amino-1,3-propanediol compounds, analogs thereof and salts thereof, particularly 2-amino-2-[2-(4-octylphenyl)ethyl]-propane-1,3-diol or a pharmaceutically acceptable salt thereof in an organic solvent or semi-aqueous solvent and methods for administration of the undiluted and diluted concentrate are provided.... Agent: Novartis Corporate Intellectual Property

20080096973 - Z-stilbenes derivatives and the pharmaceutical composition thereof: A series of Z-stilbenes derivatives are disclosed, which have the structure as shown by formula 1. In the structure of formula 1, X is hydrogen, NHR, or nitro group, and R is hydrogen. Y and Z is independently hydrogen, halogen, C1-C10 alkyl, or C1-C10 alkoxyl. Furthermore, A is hydrogen, hydroxyl,... Agent: Bacon & Thomas, PLLC

20080096974 - Polyamine-metal chelator conjugates: Many metal chelators have polar or charged functional groups, which render them difficult to transport across a cell membrane. Polyamine-metal chelator conjugates of the invention are compounds comprising a first moiety which is a metal chelator and a second moiety which is a polyamine, where the polyamine moiety includes three... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080096976 - Method of treating spinal internal disk derangement: A method of treating a spinal disk according to the present invention can include inserting an alloplastic bulking agent into the spinal disk to treat the defect. The alloplastic bulking agent has a plurality of microparticles. The bulking agent results in at least one of sealing the defect, increasing a... Agent: Knobbe Martens Olson & Bear LLP

20080096975 - Thermoresponsive, biodegradable, elastomeric material: Provided are novel biocompatible copolymers and compositions comprising the copolymers. The copolymers and degradation products thereof are non-toxic and typically have an LCST between room temperature and 37° C. so that they are liquid at room temperature and gelled at 37° C. which facilitates their use in humans, for example... Agent: Jesse A. Hirshman, Esq.

20080096977 - Biocompatible phase invertable proteinaceous compositions and methods for making and using the same: Biocompatible phase invertable proteinaceous compositions and methods for making and using the same are provided. The subject phase invertable compositions are prepared by combining a proteinaceous substrate and a cross-linker. The proteinaceous substrate includes one or more proteins and an adhesion modifier, and may also include one or more of:... Agent: Bozicevic, Field & Francis LLP

20080096978 - Ophthalmic solutions: An ophthalmic solution comprising a hydrogen peroxide source in an amount sufficient to result in between about 0.001% and about 0.01% by weight stabilized hydrogen peroxide in said formulation as a preservative, one or more ocularly-compatible hydrogen peroxide stabilizers, hydroxypropylmethylcellulose and sodium carboxymethylcellulose, as well as pharmaceutical compositions comprising such... Agent: Novartis Corporate Intellectual Property

20080096979 - Aqueous pharmaceutical coating: Novel, stable aqueous coating dispersions of wax or combination of waxes are described. The composition apart from wax includes an emulsifier and a plasticizer. The pharmaceutical applications of the dispersion include taste masking, stabilization and release retardation of drugs.... Agent: Darby & Darby P.C.

20080096980 - Methods and compositions for reducing a level of a toxic protein in a cell: The present invention provides a method of reducing a level of a toxic protein in the cytosol of a cell, the method generally involving contacting the cell with an agent that induces a survival response by the cell. The present invention provides a method of reducing a level of a... Agent: Bozicevic, Field & Francis LLP

20080096981 - Antibodies against inducible th2 cell factors: A novel TH2 associated gene that is induced by IL-9 has been identified and isolated, thereby providing a therapeutic target for IL-9 mediated diseases such as atopic allergy and asthma-related disorders. The invention also includes methods for the identification and use of small molecule inhibitors of this gene and its... Agent: Morgan Lewis & Bockius LLP

20080096982 - Methods for treatment with bucindolol based on genetic targeting: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor... Agent: Fulbright & Jaworski L.L.P.

20080090755 - Follistatin variant polypeptide: The object of the present invention is to provide a follistatin variant capable of specifically inhibiting GDF-8 activity without inhibiting activin activity. The present invention provides a follistatin variant polypeptide, which (a) comprises follistatin domain I; (b) does not comprise an amino acid sequence that is represented by formula (I):... Agent: Greenblum & Bernstein, P.L.C

20080090770 - Modulation of muc1 mediated signal transduction: The present invention provides compositions and methods for inhibiting the binding of the carboxy-terminus of MUC1 to PDZ domain(s) and to enhance the sensitivity of MUC1 expressing cancer cells to chemotherapeutic agents.... Agent: Fulbright & Jaworski L.L.P.

20080090775 - Antagonist of teb4 and methods of use: The invention concerns antagonists of TEB4 which have therapeutic activity in oncology applications and methods for selecting such antagonists... Agent: Philip S. Johnson Johnson & Johnson

20080090780 - Storage stable azadirachtin pesticide formulation: A storage stable, efficacious pesticide formulation is provided that is dilutable by the user and contains azadirachtin (AZA) and a pyrethrin or pyrethroid (PYR), and optionally an aprotic solvent and non-ionic, substantially water-free emulsifier. A sufficient amount of the PYR is provided to complex with the AZA A on opposite... Agent: Hovey Williams LLP

20080090781 - Formulations containing alkylphosphocholines using novel negative charge carriers: The invention relates to novel medicament formulations containing, as active ingredients, alkylphosphocholines and the like, alkyl-alkanediol-phosphocholines and the like, and (ether)lysolecithines and the like, in different forms of embodiment. Said active ingredients are integral constituents of liposomes, also containing cholesterol and the like and a negative charge carrier. The medicament... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080090752 - Anti-tumor vasculature effects of human serum albumin derivatives: The invention relates to a pharmaceutical composition, methods for its use and kits comprising the pharmaceutical composition, wherein the composition comprises: (a) a carrier portion; (b) a targeting portion, wherein said targeting portion comprises a targeting peptide; and (c) an immune response triggering portion, wherein said immune response triggering portion... Agent: Foley And Lardner LLP Suite 500

20080090751 - Method of promoting healing of a tympanic membrane perforation: The present invention relates to the use of plasminogen and plasmin as agents for enhancing healing of tympanic membrane perforations or other wounds, and for reducing scars or necrotic tissue forming during wound healing. The invention also relates to a method for screening of compounds which enhance wound healing by... Agent: Darby & Darby P.C.

20080090750 - Novel antiangiogenic peptide agents and their therapeutic and diagnostic use: The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy... Agent: Sutherland Asbill & Brennan LLP

20080090749 - Prophylactic/therapeutic agent for stress-induced bowel disease: Provided are a prophylactic/therapeutic agent for a stress-induced bowel disease, containing, as an active ingredient, at least one kind selected from the group consisting of histidine, a peptide comprising histidine, a precursor thereof and a pharmacologically acceptable salt thereof, a food/beverage having prophylactic/ameliorating action on the disease, a suppressant of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080090753 - Rapid acting injectable insulin compositions: Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration, In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080090754 - Sustained release formulation: A composition comprises a protein, a polyol, and a metal. The protein is stabilized by the polyol and the metal, and is protected from denaturing when in contact with an organic solvent. The polyol may be a hydrocarbon containing two or more hydroxyl groups (—OH) bonded to carbon. The metal... Agent: Evan Law Group LLC

20080090756 - Somatostatin agonists: c

20080090757 - Kahalalide compositions for the treatment of psoriasis: Kahalalide compounds, in particular kahalalide F, are of use in a method to treat a mammal suffering from skin disease such as psoriasis while avoiding toxicity and leading to clinical improvement.... Agent: King & Spalding

20080090758 - Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof: The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080090759 - Methods and kits for predicting risk for preterm labor: The invention is directed to kits and methods that allow one to predict the risk for preterm labor in a pregnant woman. The inventors have discovered that various extracellular matrix components can be detected in cervical secretions. The quantification of certain extracellular matrix proteins found within cervical secretions can be... Agent: Sonnenschein Nath & Rosenthal LLP

20080090767 - Agent for prophylaxis of reflex sympathetic dystrophy after cerebral apoplexy: The present invention is intended to provide a novel pharmaceutical agent having an excellent preventive effect on post-stroke RSD. The present invention provides an agent for preventing the onset of post-stroke RSD, comprising natural calcitonin or a calcitonin derivative as an active ingredient. The present invention is also intended to... Agent: Birch Stewart Kolasch & Birch

20080090760 - Compositions and methods for inhibiting cellular proliferation: Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise peptide molecules, optionally containing one or more individual peptide chains covalently linked, and optionally modified with polyethylene glycol (PEG). The methods involve... Agent: King & Spalding LLP

20080090765 - Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage: The invention is directed to compositions comprising two or more compounds selected from the group consisting of stem cell factor, cytokine like factor-1, CXCL14, FRAS1, neuropeptide Y, Semaphorin 3C, Cyr 61, USAG-1, IGF-BP2, WNT 6, WNT 9B, SHH, BMP-7, kit ligand, SOSTDC1, semaphorin 4D, NME3, laminin gamma 2, laminin alpha... Agent: Wilmerhale/columbia University

20080090762 - Epithelum-derived t-cell factor: Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.... Agent: Davis Wright Tremaine, LLP/seattle

20080090761 - Method comprising nanofiltration to obtain an mbl product safe from infectious agents and the product obtainable by this method: The present nanofiltration method is applicable on solutions of plasma-derived and recombinantly produced MBL. The MBL containing solution is subjected to a pre-treatment prior to the nanofiltration step. The nanofiltration is used for removal of viruses in general and other infectious agents to obtain an MBL product free from infectious... Agent: Howson And Howson

20080090763 - Novel gene encoding a dna repair enzyme and methods of use thereof: An isolated nucleic acid molecule encoding a human DNA repair enzyme, MED1, is disclosed. Like other mismatch repair genes which are mutated in certain cancers, MED1, encoding nucleic acids, proteins and antibodies thereto may be used to advantage in genetic or cancer screening assays. MED1, which recognizes and cleaves DNA,... Agent: Dann, Dorfman, Herrell & Skillman

20080090764 - Pegylated g-csf polypeptides and methods of producing same: A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to... Agent: Maxygen, Inc. Intellectual Property Department

20080090766 - Preventive or therapeutic agents for diseases including interleukin-18 inhibitor as an active ingredient: The invention provides novel curative remedies and a therapeutic method for chronic obstructive pulmonary disease, alveolar proteinosis and circulatory diseases. Disclosed is a preventive or therapeutic agent for chronic obstructive pulmonary disease, alveolar proteinosis and circulatory diseases comprising at least one of the substances selected from (1) to (4): (1)... Agent: Arendt & Associates Intellectual Property Group

20080090768 - Recombinant bone morphogenetic protein heterodimers, compositions and methods of use: The present invention relates to methods for producing recombinant heterodimeric BMP proteins useful in the field of treating bone defects, healing bone injury and in wound healing in general. The invention also relates to the recombinant heterodimers and compositions containing them.... Agent: Wyeth/finnegan Henderson, LLP

20080090769 - Treatment of psoriasis through down-regulation of the egf-receptor with topically applied egf: From unrelated but similar fields it is deduced that certain forms of psoriasis can be effectively treated through topical application of EGF-containing formulations. This patent application summarizes the theoretical basis for this finding and requests protection for the idea, while clinical evaluation is in preparation.... Agent: Bell, Boyd, & Lloyd LLP

20080090771 - Abuse-resistant hydrocodone compounds, compositions and methods of using the same: The invention relates to compounds, compositions and methods comprised of a chemical moiety attached to hydrocodone. The invention provides embodiments that provide a decrease in the potential of hydrocodone to cause overdose or to be abused while still delivering therapeutic activity similar to that of the parent hydrocodone. The invention... Agent: Darby & Darby P.C.

20080090772 - Oligosaccharide aldonic acids and their topical use: Compositions comprising oligosaccharide aldonic acids are useful for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatological disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and... Agent: Goodwin Procter LLP

20080090773 - Macrolones - amino substituted quinolones: m

20080090774 - Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations: The invention encompasses nucleoside compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.... Agent: Jones Day

20080090776 - Eml4-alk fusion gene: The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion... Agent: Sughrue Mion, PLLC

20080090777 - Long lasting drug formulations: The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes a therapeutic polypeptide, such... Agent: Pearl Cohen Zedek Latzer, LLP

20080090778 - Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof: Polynucleotides encoding telomerase reverse transcriptase (TERT) fusion proteins are provided, the TERT fusion proteins comprising a TERT protein, or functional variant thereof, fused to a substantial portion of the B subunit of heat labile enterotoxin (LTB). TERT variants useful in TERT-LTB fusion proteins of the invention comprise mutations that function... Agent: Merck And Co., Inc

20080090779 - Antiallergic agents: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring... Agent: Greenblum & Bernstein, P.L.C

20080090782 - Materials and methods to potentiate cancer treatment: Compounds that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, methods to sensitize cells the agents that cause DNA lesions, and methods to potentiate cancer treatment are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20080090784 - Crystalline form of the zoledronic acid, a process to obtain it and the pharmaceutical composition comprising it: A new crystalline form of the Zoledronic acid, characterized by its X-rays diffractogram as well as by its spatial atomic distribution in the red crystalline and its curves of thermal analysis. There is also included a method to obtain this crystalline form, which includes the synthesis of the corresponding acid... Agent: Akerman Senterfitt

20080090783 - Lpa receptor agonists and antagonists and methods of use: Disclosed are compounds according to formula (I) as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating... Agent: Donna J. Russell

20080090785 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsinlike activity of the 20S proteasome may be selectively inhibited with the inventive compounds.... Agent: Ropes & Gray LLP

20080090786 - Fluorophosphonocinnamic compounds, synthesis and uses for treating disorders caused by oxidative stress: R8 being selected from: H, an alkyl group, an aryl group, TBDPS representing a tert-butyldiphenylsilyl group; in said process said compound is reacted with a fluorinating agent comprising a complex formed between a tertiary amine and hydrogen fluoride. The invention extends also to novel fluorinated compounds so prepared and to... Agent: Young & Thompson

20080090788 - Chemical compounds:

20080090787 - Thrombopoietin mimetics: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080090789 - Tigecycline crystalline forms and processes for preparation thereof: The present invention relates to solid crystalline Tigecycline, and crystalline forms thereof.... Agent: Kenyon & Kenyon LLP

20080090790 - Pharmaceutical composition comprising a corticosteroid and a specific inhibitor of hedgehog/smoothened signaling: This invention concerns the use of cyclopamine, a naturally occurring steroidal alkaloid known for over thirty years, for the treatment of psoriasis and achievement of rapid clearance of the psoriatic skin lesions together with the reversion of the histopathological signs of disease to normalcy with no detectable side effects. The... Agent: Vidas, Arrett & Steinkraus, P.A.

20080090791 - Cystic fibrosis treatment methods: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.... Agent: Hollis-eden Pharmaceuticals, Inc.

20080090792 - Selective glucocorticoid receptor agonists: This invention is directed to a method for treating an inflammatory condition, treating haematological and other malignancies, causing immunosuppression, or preventing or treating transplant rejection in man or other animals which comprises administering to a patient a compound that has the structure of Formula (I) or Formula (II) as defined... Agent: Banner & Witcoff, Ltd.

20080090793 - Compounds and methods for the treatment of cancer: The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.... Agent: Ropes & Gray LLP

20080090797 - {beta}-lactamyl vasopression v1a antagonists and methods of use: Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.... Agent: Barnes & Thornburg LLP

20080090801 - 4-methylpyridopyrimidinone compounds: v

20080090800 - Mandelic acid derivatives and their use as thrombin inhibitors: There is provided a compound of formula (I) wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus,... Agent: Morgan Lewis & Bockius LLP

20080090799 - 2-pyridinecarboxamide derivative having gk-activating effect: R11 and R12 each independently represent a hydrogen atom or a lower alkyl group, or taken together with the nitrogen atom to which they bond, R11 and R12 may form a 4- to 7-membered nitrogen-containing aliphatic ring (one carbon atom constituting the 4- to 7-membered nitrogen-containing aliphatic ring may be... Agent: Merck And Co., Inc

20080090798 - Heterocyclic substituted aminoazacycles useful as central nervous system agents: 1

20080090795 - Pharmaceutical compositions based on nk2 antagonists for pediatric use: Pharmaceutical compositions containing NK2 antagonists are described, useful for the treatment of infantile colics.... Agent: Abelman, Frayne & Schwab

20080090796 - Piperidine and azetidine derivatives as glyt1 inhibitors: The present invention provides compounds of formula (I), wherein both p's are one or two, R1 is generally heteroaryl or cycloalkyl, R2 is C3-6cycloalkyl or phenyl and R3 is heteroaryl, and pharmaceutically acceptable salts thereof, as GlyT1 inhibitors for treating schizophrenia, pharmaceutical compositions comprising the same and methods for their... Agent: Merck And Co., Inc

20080090794 - Potassium channel inhibitors: e

20080090802 - Quinazolinone and isoquinolinone acetamide derivatives:

20080090803 - Fatty alcohol drug conjugates: The invention provides conjugates of fatty alcohols and pharmaceutical agents useful in treating cancer, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparation of the fatty alcohols-pharmaceutical agent conjugates are provided.... Agent: Wolf Greenfield & Sacks, P.C.

20080090804 - New progesterone receptor modulators: The present invention provides new progesterone receptor modulators which are (cis)-8-fluorodibenzo[b,f]pyrido[1,2-d]oxazepine-1-amine compounds and uses thereof.... Agent: Organon Usa, Inc. Patent Department

20080090805 - Cb-1 modulating compounds and their use: Disclosed herein is a compound of Formula (I). Also disclosed herein is a method of modulating the activity of a cannabinoid receptor using a compound of Formula (I). Furthermore, disclosed herein is a method of treating a disease or condition that would be alleviated, improved or prevented by administration of... Agent: Knobbe Martens Olson & Bear LLP

20080090806 - Cgrp receptor antagonists: The present invention is directed to compounds of Formula (I) and Formula (II) (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases... Agent: Merck And Co., Inc

20080090807 - Lactam-containing compounds and derivatives thereof as factor xa inhibitors: e

20080090808 - Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction: The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke,... Agent: Frank Volvovitz

20080090809 - Pyrazole compounds: e

20080090810 - Thiophene compounds:

20080090811 - Carbamate compounds as 5-ht4 receptor agonists:

20080090812 - Pyrrolobenzodiazepine therapeutic agents useful in the treatment of leukemias: A pyrrolobenzodiazepine dimer compound of Formula (I): or pharmaceutically acceptable salt or solvate thereof is useful as a therapeutic agent for the treatment of leukaemias, especially B-cell leukaemias, that exhibit resistance to other chemotherapeutic drugs, wherein: the dotted lines indicate the optional presence of a double bond between C1 and... Agent: Michael Best & Friedrich LLP

20080090813 - 4-phenyl-pyrimidine-2-carbonitrile derivatives: wherein each of the substituents is given the definition as set forth in the specification and claims, or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising the derivatives as well as to the use thereof in the treatment of osteoporosis, atherosclerosis, inflammation and immune disorders,... Agent: Organon Usa, Inc. Patent Department

20080090814 - Pyridazinone compounds: The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.... Agent: Connolly Bove Lodge & Hutz LLP

20080090815 - Substituted oxazolidinones and their use in the field of blood coagulation: e

20080090816 - Anti-infective biaryl compounds:

20080090817 - Bridged n-cyclic sulfonamido inhibitors of gamma secretase: wherein A is as described in the specification and R1 and R2 combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080090819 - Derivatives of [6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide: Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080090818 - Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases: r

20080090820 - Novel crystalline form of linezolid: The present invention relates to a novel crystalline form of linezolid, to processes for its preparation and to a pharmaceutical composition containing it.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20080090821 - Substituted tetrahydroisochinolines as mmp inhibitors, related production method and use as medicine: e

20080090822 - Piperazine derivatives as glyt 1 inhibitors: The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, n, X, Y and Z are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080090823 - Thiadiazoles as cxc- and cc- chemokine receptor ligands: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080090824 - Novel crystalline form of linezolid: The present invention relates to a novel crystalline form of linezolid, to processes for its preparation and to a pharmaceutical composition containing it.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20080090825 - Metallo-beta-lactamase inhibitors: A new metallo-β-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of β-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-β-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of β-lactam antibiotics against metallo-β-lactamase producing bacteria... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080090826 - Muscarinic modulators: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Jonathan P. O'brien Miller, Canfield, Paddock And Stone

20080090827 - Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure: This invention provides compounds that possess inhibitory activity against β-adrenergic receptors and phosphodiesterase PDE, including phosphodiesterase 3 (PDE3). This invention further provides pharmaceutical compositions comprising such compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds... Agent: Seed Intellectual Property Law Group PLLC

20080090828 - N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines: It has now been found that certain novel N-(substituted aryl)-4-(disubstituted methyl)piperidine and pyridine derivatives have provided unexpected insecticidal activity. These compounds are represented by formula (I): wherein m, n, q, r, and s are independently selected from 0 or 1; and p is 0, 1, 2, or 3; A is... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080090829 - Substituted heteroaryl- and phenylsulfamoyl compounds: The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including... Agent: Pfizer Inc.

20080090830 - Bicyclic and tricyclic derivatives as thrombin receptor antagonists: represents an optional double bonds the dotted line is optionally a bond or no bonds resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R3, R10, R11, R32 and R33 are herein defined and the... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080090831 - Cytotoxic agents: The invention provides compounds of the invention pharmaceutical compositions comprising a compound of the invention, processes for preparing compounds of the invention, intermediates useful for preparing compounds of the invention, and therapeutic methods for treating cancer and other topoisomerase mediated conditions.... Agent: Viksnins Harris & Padys Pllp

20080090832 - Methods and compositions for the treatment of metabolic disorders: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.... Agent: Marshall, Gerstein & Borun LLP

20080090833 - Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha: Solvates and crystalline forms of imatinib mesylate are described. Further, methods for preparing such solvates and crystalline forms of imatinib mesylate are described.... Agent: Kenyon & Kenyon LLP

20080090834 - Selective azole pde10a inhibitor compounds: as defined herein, that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS)... Agent: Pfizer Inc Steve T. Zelson

20080090835 - Polymorphic forms of ziprasidone hcl and processes for their preparation: Provided are various polymorphic forms of ziprasidone HCl and processes for their preparation.... Agent: Kenyon & Kenyon LLP

20080090836 - Pyrazole compounds useful in the treatment of inflammation: There is provided compounds of formula (I), wherein Ra, Rb, R1, R2, R3, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required,... Agent: Morgan Lewis & Bockius LLP

20080090837 - Biaryls useful as modulators of ion channels: The present invention relates to compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20080090838 - N-hydroxyamide derivatives and use thereof: The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic 5 obstructive pulmonary disease, liver and pulmonary fibrosis.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080090839 - Phenoxymethylalkyne inhibitors of lta4h for treating inflammation: is disclosed. In these compounds Q and Z are (CH2)1-10; in which one or two (CH2) may optionally be replaced by —O—, —NR1—, —SO—, —S(O)2—, —C(═O)— or —C═O(NH)—; Het is a 5-7 membered non-aromatic nitrogen heterocycle; and W is acyl, hydroxyl, carboxyl, amino, carboxamido, aminoacyl, —COOalkyl, —CHO, heterocyclyl, substituted aryl,... Agent: Heslin Rothenberg Farley & Mesiti PC

20080090840 - Heterocyclic gpr40 modulators:

20080090841 - Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes: The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080090842 - Novel pyridyl cyanoguanidine compounds: wherein R1 represents hydrogen, halogen or one or more straight or branched, saturated or unsaturated C1-6 hydrocarbon radical, optionally substituted with halogen, hydroxy, cyano, nitro, carboxy, alkoxy, alkoxycarbonyl, alkylcarbonyl, formyl, amino, aminoalkyl, aminocarbonyl, alkylcarbonylamino, sulfo, aminosulfonyl, alkylsulfonylamino, hydroxysulfonyloxy, dihydroxyphosphinoyloxy or phosphono; X represents a straight or branched, saturated or unsaturated... Agent: Wilmerhale/boston

20080090843 - Inhibition of the src kinase family pathway as a method of treating hbv infection and hepatocellular carcinoma: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src 5 tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as... Agent: Jones Day

20080090844 - 3-beta-d-ribofuranosylthiazalo [4-5-d] pyrimidine nucleosides and uses thereof: The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.... Agent: Connolly Bove Lodge & Hutz LLP

20080090846 - Chemokine receptor binding heterocyclic compounds: Tertiary amines containing a multiplicity of heteroaromatic substituents are useful as chemokine receptor modulators.... Agent: Morrison & Foerster LLP

20080090845 - Haloalkyl-substituted pyrimidinone derivatives: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods... Agent: Edward Angell Palmer & Dodge, LLP Client: Neurogen Corporation

20080090847 - Heterocyclic compounds and uses thereof as d-alanyl-d-alanine ligase inhibitors: The invention is based on the discovery of a new class of heterocyclic compounds having, for example, antibacterial properties. The D-Ala-D-Ala ligase enzyme is a critical pathway enzyme in the bacterial cell-wall synthesis. The compounds can bind to and inhibit the enzyme D-Ala-D-Ala ligase. The new compounds' activity combined with... Agent: Darby & Darby P.C.

20080090850 - Herpetic neuralgia topical treatment: Compositions and methods for treatment of acute herpetic zoster and post herpetic neuralgia. The compositions comprise the combination of five or six components, namely, a carrier penetrator, an anti-inflammatory agent, a topical analgesic, a nonsteroidal anti-inflammatory penetrator, a direct-application anti-viral agent, and, optionally, an anti-convulsant and calcium-channel blocker. The compositions... Agent: Stetina Brunda Garred & Brucker

20080090849 - Novel purine derivatives, preparation method and use as medicines: m

20080090848 - Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides: The present invention describes new biological activities of immunomodulating 6-substituted purinyl compounds which make them particularly useful during the treatment of cancer. Collectively, these new biological activities make these purinyl compounds useful chemoprotective agents for the treatment of myelosuppression which is associated with cancer chemotherapy and/or radiotherapy. This chemoprotective activity... Agent: Nixon & Vanderhye, PC

20080090851 - Bicyclic heteroaromatic compounds: e

20080090852 - Bicyclic heteroaromatic compounds:

20080090853 - Bicyclic heteroaromatic compounds:

20080090854 - Cxcr2 inhibitors: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080090855 - Substituted cyclic urea derivatives and the use thereof as vanilloid receptor 1 modulators: The present invention relates to substituted cyclic urea derivatives corresponding to formula I, to processes for the preparation thereof, to medicinal drugs containing such compounds, to the use of such compounds in the preparation of medicinal drugs and in related treatment methods.... Agent: Crowell & Moring LLP Intellectual Property Group

20080090856 - Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases: The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules... Agent: Hovey Williams LLP

20080090857 - Statin derivatives: Statin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for treating and/or preventing several diseases, in particular coronary syndromes, neurodegenerative disorders as well as for reducing cholesterol levels.... Agent: Arent Fox LLP

20080090858 - Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands: A chemical compound of formula (I) wherein R1 and R2 are independently selected from hydrogen and alkyl; R3 is alkyl; R4 and R5 are selected from hydrogen and alkyl; R6 and R7 are independently selected from hydrogen, halogen, hydroxyl, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, nitro, carbonitrile,... Agent: Foley And Lardner LLP Suite 500

20080090859 - Use of selective opiate receptor modulators in the treatment of neuropathy: The instant invention relates to the use of compounds that are effective as selective opiate receptor modulators for the manufacture of a pharmaceutical for the diagnosis, prophylaxis and/or the treatment of neuropathy, the clinical pictures and symptoms associated therewith, and related disorders, and to pharmaceutical compositions, comprising one or more... Agent: Morrison & Foerster LLP

20080090860 - Retinoid x receptor modulators: e

20080090861 - Therapeutic pyrazolyl thienopyridines: wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more... Agent: Pfizer Inc.

20080090862 - Isoquinoline derivatives as calpain inhibitors: The invention relates to derivative compounds of partially-reduced isoquinoline with substitution of a sec-butyl group at position 3 with calpain inhibitor activity. The inventive compound comprises an ester or amide derived from (3-sec-butyl-1-oxo-2,3-dihydro-1H-isoquinolin-4-yliden)-acetic acid and (3-sec-butyl-1-thioxo-2, 3-dihydro-1H-isoquinolin-4-yliden)-acetic acid. Compounds having formula I or II can be used in the preventive... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080090863 - Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor: which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental... Agent: Sughrue Mion, PLLC

20080090865 - Antidiabetic bicyclic compounds: Bicyclic compounds containing a fused pyridine ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and... Agent: Merck And Co., Inc

20080090864 - Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide: Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein.... Agent: Fish & Richardson PC

20080090866 - Cosmetic use of piperidine derivatives: a

20080090867 - Azole derivatives in the form of lipase and phospholipase inhibitors: as defined in the present application as well as to their uses in treatment of conditions that would benefit from their inhibitory effect on hormone sensitive lipase, HSL, an allosteric enzyme in adipocytes which is inhibited by insulin and is responsible for the breakdown of fats in fat cells and... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080090868 - Amide-substituted 8 n benzimidazoles, method for the production thereof, and use of the same as medicaments:

20080090870 - Amino-substituted 8-n-benzimidazoles and methods for their use in blood sugar disorders:

20080090869 - Aminocarbonyl-substituted 8-n-benzimidazoles, methods for their preparation and their use in pharmaceutical compositions:

20080090871 - Cannabimimetic indole derivatives: Novel cannabimimetic indole derivatives are presented which have preferentially high affinities for one of the cannabinoid CB1 or CB2 receptors. The improved receptor affinity makes these analogs therapeutically useful as medications in individuals and animals for treatment of pain, glaucoma, epilepsy, nausea associated with chemotherapy.... Agent: Alix Yale & Ristas LLP

20080090872 - Dipyrazole compounds and their use as central nervous system agents: v

20080090873 - Sulfonamide derivatives:

20080090874 - Treatment of breakthrough pain in patients suffering from chronic low back pain: Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa and for the... Agent: Cima Lerner, David Et Al

20080090875 - Thione derivative, method for the preparation thereof, and pharmaceutical composition containing the same: A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080090876 - Use of thianecarboxamides as dgat inhibitors: 1

20080090879 - Method of treatment: Improvements in the treatment of patients suffering from frequent heartburn are provided by a treatment regimen comprising administration of an effective daily amount of lansoprazole or a pharmaceutically acceptable salt thereof for up to 14 days.... Agent: Novartis Consumer Health, Inc.

20080090878 - Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders: The present invention relates to a combination of a first agent including either a 5-HT4 receptor agonist or antagonist or a 5-HT3 receptor antagonist and a co-agent and pharmaceutical compositions and formulations containing the combination. The present invention also relates to a method of treating a gastrointestinal and abdominal viscera... Agent: Novartis Corporate Intellectual Property

20080090877 - Salts of benzimidazole derivative with amines and process for manufacturing the same: e

20080090880 - 3-(2-hydroxyphenyl) pyrazoles and thier use as hsp90 modulators: Novel phenylpyrazole derivatives of the formula (I), in which R1-R6, X and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role... Agent: Millen, White, Zelano & Branigan, P.C.

20080090881 - Treatment of diabetes with thiazolidinedione and metformin: A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and a biguanide antihyperglycaemic agent, to a mammal in need thereof and a... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080090882 - Heterocyclic carbonyl compounds: Novel heterocyclic compounds of the formula (I), in which R1, D, W, T and T′ have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases... Agent: Millen, White, Zelano & Branigan, P.C.

20080090883 - Alkylene bridged sultam compounds useful as modulators of nuclear hormone receptor function: v

20080090884 - Antimicrobial [3.1.0] bicyclohexylphenyl- oxazolidinone derivatives and analogues:

20080090885 - Preparation of losartan 5-carboxylic acid and use thereof: A method for synthesis of losartan 5-carboxylic acid (EXP-3174).... Agent: Patterson, Thuente, Skaar & Christensen, P.A.

20080090886 - Aqueous fungicidal composition and use thereof for combating harmful micro organisms: The invention relates to aqueous fungicidal active substance compositions and to their use in the control of harmful microorganisms and in particular in the protection of cellulose-comprising materials, particularly wood, from infection by microorganisms, in particular those harmful fungi which can damage wood or cellulose. The active substance composition according... Agent: Birch Stewart Kolasch & Birch

20080090887 - Triazole compounds that modulate hsp90 activity: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080090888 - Methods and materials for assessing prostate cancer therapies and compounds: A modest (2-5 fold) increase in androgen receptor (AR) mRNA is the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention... Agent: Venable LLP

20080090889 - Substituted 2-aminoalkylthiobenzimidazole compounds, pharmaceutical compositions thereof and methods for their use: wherein R1-R5 and R11-R16 are hereinafter defined. These compounds, their derivatives and the pharmaceutically acceptable salts thereof are useful in the reduction of elevated blood sugar levels and are therefore useful in the treatment of hyperglycemia, diabetes, atherosclerosis and other blood sugar disorders. These compounds are particularly suitable in the... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080090890 - Substituted, bicyclic 8-pyrrolidinobenzimidazoles, methods for their production and their use as medicaments: e

20080090891 - Ion channel modulators: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel... Agent: Wyeth Patent Law Group

20080090892 - Amorphous asenapine and processes for preparing same: This disclosure relates to amorphous asenapine and pharmaceutically acceptable complexes, salts, solvates and hydrates thereof, to solid pharmaceutical compositions containing it, and to its use to treat central nervous system disorders, including schizophrenia and bipolar disorder. This disclosure also relates to methods and materials for preparing amorphous asenapine and pharmaceutical... Agent: Organon Usa, Inc. Patent Department

20080090893 - Medicinal composition for prevention of transition to operative treatment for prostatic hypertrophy: The present invention provides an agent useful for the prevention of transition to surgical therapy for benign prostatic hyperplasia and the like. The present invention relates to a pharmaceutical composition for the prevention of transition to surgical therapy for benign prostatic hyperplasia, which comprises an indoline derivative represented by the... Agent: Sughrue Mion, PLLC

20080090894 - Transdermal migraine therapy: The invention is directed to formulations and methods of treating a migraine and/or cluster headache with a serotonin agonist, pharmaceutically acceptable salt thereof, or derivative thereof.... Agent: Davidson, Davidson & Kappel, LLC

20080090895 - Novel pharmaceutical composition and their uses thereof for controlling the different forms of addiction to drugs: The invention relates to the necessaries of life, especially the field of therapeutics. The invention specifically relates to pharmaceutical compositions for helping users of addictive drugs to stop, said compositions being in the form of a combination of two medicaments consisting of a partial or full antagonist of dopaminergic receptors,... Agent: Banner & Witcoff, Ltd.

20080090896 - Strontium-based treatment of otosclerosis: The present invention is directed to a method of treating otosclerosis in a human in need thereof by administering a strontium-based compound in a defined dosing schedule. The present invention demonstrates an effective response and sustained benefit in the treatment of otosclerosis.... Agent: Baker Botts L.L.P.

20080090897 - Compositions and methods for neuroprotectin: Disclosed herein are neuroprotective compounds. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of neurodegenerative conditions are provided.... Agent: Edwards Angell Palmer & Dodge LLP Client: Jhu

20080090899 - Application of water and organic solvent soluble ivermectin for topical and oral use: A stable, palatable solution of Ivermectin in water is provided for the mass medication of animals. The present formulation does not require the use of benzyl alcohol and is stable indefinitely in the concentrated form and for up to 30 days when mixed with water.... Agent: Crowell & Moring LLP Intellectual Property Group

20080090898 - Boosting immunity: The invention relates to compositions, and methods of use thereof, for boosting immunity, e.g. innate immunity, in a subject in need thereof comprising administering to the subject certain polyphenols such as flavanols, procyanidins, or pharmaceutically acceptable salts or derivatives thereof.... Agent: Nada Jain, P.C.

20080090900 - Antibiotic bushrin: This invention describes a new antibiotic, hereinafter designated as bushrin, having the formula C16H16O2, which is 7-(3-furyl)-3,7-dimethyl-7,8-dihydro-1-naphthalenol, its production method by fermentation, and the methods related to its recovery, concentration and purification from the crude solutions. The invention includes within its scope the agent in dilute form, as a crude... Agent: Sarfaraz K. Niazi

20080090901 - Process to obtain dibenzylbutyrolactonic lignans, process to obtain synthetic derivatives from lignans bearing anti-chagas chemoprophylactic and therapeutical activities: The invention refers to a process to obtain lignans, especially to obtain cubebin and methylpluviatolide from leaves of Zanthoxylum naranjillo or Piper cubeba. It also refers to a process to obtain semi-synthetic derivatives of cubebin, especially dibenzylbutirloactonic lignans, such as: hinokinin, o-acetyl cubebin, o-methyl cubebin, 6,6′-dinitrohinokinin and o-dimethylethylamine cubebin and... Agent: Volpe And Koenig, P.C.

20080090903 - Phenylalkyl carbamate compositions: The present invention relates to a composition of a phenylalkyl carbamate compound that results in improved stability, wherein the composition comprises a phenylalkyl carbamate compound in a mixture with an effective amount of one or more excipients and, wherein at least one excipient is dibasic calcium phosphate dihydrate.... Agent: Philip S. Johnson Johnson & Johnson

20080090902 - Phenylalkylamino carbamate compositions: The present invention relates to a composition of a phenylalkylamino carbamate compound that results in improved stability, wherein the composition comprises a phenylalkylamino carbamate compound in a mixture with an effective amount of one or more excipients wherein at least one excipient is dibasic calcium phosphate dihydrate.... Agent: Philip S. Johnson Johnson & Johnson

20080090904 - Phenylalkyl carbamate compositions: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have... Agent: Ropes & Gray LLP

20080090905 - Amine salts of (-)-2-((2-(4-hydroxyphenyl)ethyl)thio)-3-(4-(2-(4-((methylsulfonyl)oxy)phenoxy)ethyl)phenyl) propanoic acid: A cinchonidine salt, an (R)-(+)-1-(1-naphthyl)ethylamine salt and a (S)-(−)-1-(2-naphthyl)ethylamine salt of (−)-2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid, processes for their preparation, their use in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance and other manifestations of the metabolic syndrome, and pharmaceutical compositions containing them.... Agent: Morgan Lewis & Bockius LLP

20080090906 - Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction: The use of acetyl L-carnitine in combination with propionyl L-carnitine and sildenafil is described for the preparation of a medicament and/or dietetic product for the treatment of erectile dysfunction secondary to all those conditions in which there is distress or iatrogenic damage of the lesser pelvis within which the neurovascular... Agent: Lucas & Mercanti, LLP

20080090907 - Crystal comprising (2r)-2-propyloctanoic acid and amine: Crystals comprising (2R)-2-propyloctoic acid and an amine which retain the pharmacological effect of (2R)-2-propyloctoic acid and can be safely used as a medicinal raw drug for peroral solid preparations. Of these crystals, the crystals especially with dibenzylamine are advantageous because not only the crystals themselves are useful as a medicinal... Agent: Sughrue-265550

20080090908 - Use of triglyceride oils containing gamma-linolenic acid residues and linoleic acid residues for the treatment of neurodegenerative disease: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both γ-linolenic acid and linolenic acid residues as triglyceride ester, the ratio of γ-linolenic acid to linolenic acid residues at... Agent: Nixon & Vanderhye, PC

20080090909 - Ship 1 modulators: The present invention includes the use of pelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIP 1 activity. This invention also provides novel terpene compounds capable of modulating SHIP 1 activity and methods of synthesis thereof.... Agent: Bozicevic, Field & Francis LLP

20080090910 - Methods for treatment of nocturia: A method for the treatment of nocturia which consists of administering to a mammal in need of such treatment a therapeutically effective amount of a nonsteroidal anti-inflammatory drug consisting of loxoprofen or a pharmacologically acceptable salt thereof, wherein the mammal has a neurogenic bladder.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080090911 - Stabilized prostaglandin e composition: A prostaglandin E composition comprises are substantially free from C1-C4 alcohols and include the prostaglandin E compound together with a (C1-C4)-alkyl (C8-C22) carboxylic ester (e.g., ethyl laurate), an N,N-di(C1-C8) alkylamino substituted, (C4-C18) alkyl (C2-C18) carboxylic ester and/or a pharmaceutically acceptable addition salt thereof, and optionally, a viscosity enhancing agent such... Agent: Olson & Cepuritis, Ltd.

20080090912 - Compositions containing prodrugs of florfenicol and methods of use: The present invention provides compositions and methods for administering florfenicol to mammals. The compositions contain a prodrug of florfenicol in a pharmaceutically acceptable carrier. In one embodiment the prodrug is an esterized form of florfenicol. Examples of suitable prodrugs include one or a combination of one or a combination of... Agent: Kenyon & Kenyon LLP

20080090913 - Sphingolipid-derived phamaceutical compositions: The present invention relates to specific sphingolipids/sphingolipid derivatives as pharmaceutical compositions as well as their use in the preparation of medicaments for the treatment, prevention and/or amelioration of disorders relating to pathological processes in lipid rafts.... Agent: Fulbright & Jaworski L.L.P.

20080090914 - Staining composition for staining an ophthalmic membrane: A staining composition for staining an ophthalmic membrane when performing the ophthalmic membrane removal, wherein the staining composition comprises a Brilliant Blue G (BBG) derivative as a primary component.... Agent: Osha Liang L.L.P.

20080090915 - Method for preventing or attenuating anthracycline-induced cardiotoxicity: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or attenuation of anthracycline-induced cardiotoxicity.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080090916 - Compounds for treating urinary incontinence: The invention relates to compounds of formula (I) or a pharmaceutically acceptable solvate or salt thereof, including a solvate of such a salt, wherein R1 is a group such that a compound of formula (I) is a prodrug of 1R,2S-methoxamine that is converted within the kidney tubules into its active... Agent: Leon R. Yankwich Yankwich & Associates

20080090917 - Antimicrobially active compositions: Compositions (3) and methods of using such compositions (3) to condition, clean, or disinfect the flow path of a conduit (8) of a microfluidic devices (16), such as flow cytometers or liquid chromatographs.... Agent: Cr Miles, P.C. Craig R. Miles

20080085852 - Use of xikvav peptides in the preparation of cosmetic compositions which are intented to improve the firmness of the skin by increasing cell adhesion: The invention relates to cosmetic compositions which are intended to improve the firmness of the skin by increasing adhesion of cutaneous cells in relation to one another and the basal lamina. The aforementioned compositions comprise a cosmetically-effective quantity of peptides having general formula X-isoleucyl-lysyl-valyl-alanyl-valine-Y, known as XIKVAV (FIG. 1). The... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20080085858 - Pharmaceutical composition: The present invention provides a pharmaceutical composition comprising (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) an immunosuppressant, a therapeutic and/or preventive agent for chronic skin diseases comprising (a) a PDE-IV inhibitor or a pharmaceutically acceptable salt thereof and (b) an immunosuppressant, a therapeutic and/or... Agent: Fitzpatrick Cella Harper & Scinto

20080085859 - Drug promoting ceramide transport, base sequence for producing the drug, method of measuring activity of promoting ceramide release and method of measuring activity of promoting intermembrane ceramide transfer: A drug for promoting ceramide transport contains a protein having the amino acid sequence of SEQ ID NO:1 as an effective component; the base sequence of SEQ ID NO:3; a method of measuring an activity for promoting ceramide release comprises mixing a lipid membrane containing ceramide with a drug promoting... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080085860 - Selective vpac2 receptor peptide agonists: The present invention encompasses PEGylated peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.... Agent: Eli Lilly & Company

20080085856 - Modified chimeric cry35 proteins: This invention provides modified, insecticidal Cry35 proteins with enhanced properties as compared to wild-type Cry35 proteins. The modifications to these proteins were based in part on analysis of the atomic coordinates and three-dimensional (3D) structure of the ˜45 kDa 149B1 protein and other proteins in the Cry35 class. The subject... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080085854 - Multifunctional protease inhibitors and their use in treatment of disease: Fusion proteins of protease inhibitors are provided, in particular fusion proteins of alpha 1-antitrypsin (AAT) and a second protease inhibitor, such as secretory leukocyte protease inhibitor (SLPI) or tissue inhibitor of metalloproteases (TIMP). Polynucleotides encoding the fusion proteins, vectors comprising such polynucleotides, and host cells containing such vectors are also... Agent: Heller Ehrman LLP

20080085853 - Nuclear targeting by means of bacterial proteins: A nuclear delivery construct comprises (i) protein H or a fragment or derivative thereof that is capable of being targeted to the nucleus of a eukaryotic cell; and associated therewith (ii) one or more other components whose targeting to the nucleus of the eukaryotic cell is desired.... Agent: Kalow & Springut LLP

20080085855 - Perivascular wraps: The present invention provides compositions, devices, and methods for maintaining or improving the integrity of body passageways following surgery, such as at a graft site, or injury. Delivery devices including one or more therapeutic agents and a mesh are described. Representative examples of therapeutic agents include microtubule stabilizing agents, anti-angiogenic... Agent: Seed Intellectual Property Law Group Pllc

20080085857 - Peg conjugates of nk4: The present invention provides a conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080085865 - Factor c for treating gram-negative bacterial infection: Recombinant fragments of Factor C are disclosed. These proteins and peptides show great potency in recognizing, binding to, neutralizing and removing endotoxin. These molecules can thus be used for anti-microbial, anti-endotoxin, and anti-sepsis therapy. SSCrFCES is a 38 kDa protein representing the LPS-binding domain of Factor C. The ability of... Agent: Klarquist Sparkman, LLP

20080085861 - Gas1 polypeptides: There is disclosed a method of inhibiting the lethal effect of expressing an otherwise lethal protein in a cell, said method comprising: (a) providing a cell, tissue or organism having (i) a nucleotide sequence encoding a Gas1 protein, or a functional equivalent, derivative or bioprecursor thereof, which is capable of... Agent: Philip S. Johnson Johnson & Johnson

20080085863 - Method and composition for treating a fibrotic disorder: α2-macroglobulin-related agents for treating or preventing a fibrotic disorder associated with fibrillogenesis are disclosed along with methods for using the agents, as well as methods for producing agents suited for use in the disclosed methods for treating or preventing a fibrotic disorder.... Agent: Quarles & Brady LLP

20080085864 - Method of modifying glucose activity using polypeptides selectively expressed in fat tissue: Isolated omentin polypeptides that selectively express in omental fat tissue and methods for the use of the polypeptides. The polypeptides can be used in a method for modifying insulin action and/or glucose metabolism in an animal. The polypeptides can be used to promote glucose uptake by animal adipocytes and other... Agent: Merchant & Gould Pc

20080085862 - Natriuretic peptide conjugate using carrier substance: The present invention relates to an Natriuretic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an Natriuretic peptide, a non-peptidyl polymer and a carrier substance, which are covalently linked to each other, and a use of the same. The Natriuretic peptide conjugate of the present invention has... Agent: Seed Intellectual Property Law Group Pllc

20080085866 - Metallo-desferrioxamine complexes and their use in the treatment of bacterial infections: Methods for treating a bacterial infection by using a metallo-desferrioxamine complex.... Agent: Christensen, O'connor, Johnson, Kindness, Pllc

20080085870 - Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection: The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080085869 - Duplex oligonucleotide complexes and methods for gene silencing by rna interference: Provided herein are duplex oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene without the aid of a transfection reagent(s). The duplex oligonucleotide complexes of the disclosure include a conjugate moiety that facilitates delivery to a cell, tissue or organism.... Agent: Greenberg Traurig, LLP

20080085867 - Early detection and prognosis of colon cancers: A genome wide microarray gene expression approach for human colorectal cancer cells was used to identify hundreds of hypermethylated genes for colon cancer. We compared isogenic cells altered pharmacologically versus genetically to induce genomic demethylation, to pinpoint genes activated by DNA demethylation, but not by inhibition of class I and... Agent: Banner & Witcoff, Ltd.

20080085868 - Monoclonal antibody 3f1h10 neutralising vhsv (viral haemorrhagic septicaemia virus): The present invention relates to a non-infectious nucleic acid (RNA and DNA) construct constructed to express a recombinant antibody or antibody fragment in a host cell. The antibody molecule confers protection to the host against a pathogen, allergen or toxin. The host may be any animal including a human.... Agent: Licata & Tyrrell P.c.

20080085871 - Novel polysaccharide pro-drug 5-fluorouracil (5-fu) with enhanced target specificity for colorectal cancer and its preparation methods: This invention describes a novel polysaccharide prodrug of 5-fluorouracil (5-FU) with enhanced target specificity for colorectal cancer treatment, and its preparation methods. The prodrug is synthesized by chemically linking anti-cancer drug 5-fluorouracil (5-FU) with a specially selected polysaccharide with molecular weight of 105˜107 Da containing galactose residues. Its distinctive characteristics... Agent: Joemy C. Tam

20080085872 - Methods of treating syndrome x with aliphatic polyamines: where n is a positive integer and each R, independently, is H or a C1-C8 alkyl group; at least one aliphatic alkylating agent; and a cross-linking agent. Long term administration of the cross-linked polyamine salts of the invention increases HDL levels and decreases LDL levels in patients. The invention also... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080085873 - Disease treatment methods: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α, 17β-trihydroxyandrostane.... Agent: Hollis-eden Pharmaceuticals, Inc.

20080085874 - Small molecule potentiator of hormonal therapy for breast cancer: The present application demonstrates that HDAC inhibitors can be used in combination with hormonal therapy to treat and prevent estrogen receptor positive breast cancer. HDAC inhibitors can also be combined with IGF-1R inhibitors, mTOR inhibitors, and EGFR inhibitors to treat breast cancer, optionally in combination with hormonal therapy if indicated.... Agent: Townsend And Townsend And Crew, LLP

20080085876 - Insect sting treatment: A treatment for insect bites and stings [100] includes a mixture of a base material [101], a draw-out agent [102], an immune suppression agent [103] for reducing an immune response, and optionally, an antimicrobial agent [104]. The draw-out agent [102] functions to keep the wound moist and open. The immune... Agent: L. Zale Patent Law Office

20080085875 - Crystalline forms of 11ss-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17a-pregna-4,9-dien-3-one: The present invention relates to crystalline forms of 11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17α-pregna-4,9-dien-3-one. The invention relates in particular to two crystalline ansolvate/anhydrate forms of this compound, polymorphs I and II. However, the present invention also relates to crystalline solvates, for example methanol and ethanol solvates of 11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17α-pregna-4,9-dien-3-one as precursors for preparing these two polymorphs... Agent: Millen, White, Zelano & Branigan, P.c.

20080085877 - Therapeutic methods of using estrogen compositions: A method for preventing or treating a catamenial migrainous disorder in a female subject comprises administering to a vulvovaginal surface of the subject a pharmaceutical composition that is bioadhesive thereto and comprises at least one estrogenic compound in an amount of about 50 μg to about 1000 μg estradiol equivalent... Agent: Kv Pharmaceutical Company

20080085879 - Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation: The invention provides a method of treating an estrogen responsive condition comprising administration of an agonist of an orphan nuclear receptor, wherein activation of the orphan nuclear receptor inhibits estrogen activity. The invention also provides a method of reducing the size of an estrogen responsive tumor comprising administration of an... Agent: Leydig Voit & Mayer, Ltd

20080085878 - Superoxide dismutase-2 expression and modulation for glaucoma diagnosis and therapy: The present invention concerns a method for diagnosing or monitoring elevated intraocular pressure or glaucoma in a patient comprising providing a biological sample from the patient and measuring the expression level of a superoxide dismutase-2 (SOD-2) gene in the biological sample. The present invention also concerns methods for treating glaucoma... Agent: Alcon

20080085880 - Crystalline forms of rapamycin analogs: A rapamycin analog composition includes a crystalline form of a rapamycin analog. The crystal can be a hydrate, dehydrate, solvate, or desolvate. The rapamycin analog can have a structure of Formula 1, which is optionally a prodrug, salt, derivative, or combination thereof:... Agent: Workman Nydegger

20080085881 - Stop-and-go oxaliplatin treatment regimens: Methods of treating an oxaliplatin-sensitive cancer are disclosed in which a therapy comprising oxaliplatin is initiated, continued until a predetermined endpoint, stopped, then reintroduced after specific criteria are met. This stop-and-go approach reduces or eliminates the neurotoxicity associated with oxaliplatin administration while at the same increasing one or more of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080085882 - Compositions and methods for potentiation of cancer agents: The present invention includes compositions and method to improve the therapeutic index of anti-cancer agents using a novel anti-cancer agent and a modulator or potentiator thereof.... Agent: Chalker Flores, LLP

20080085883 - Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance: The present invention relates, in one embodiment, to a method of preventing or treating diabetes using low molecular weight antioxidants. In a further embodiment, the invention relates to a method of protecting and/or enhancing viability of cells/tissues/organs during isolation (harvesting), preservation, expansion and/or transplantation. In yet another embodiment, the present... Agent: Paul, Hastings, Janofsky & Walker LLP

20080085886 - Aza-benzofuranyl compounds and methods of use: The invention relates to azabenzofuranyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzofuranyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal.... Agent: Genentech, Inc.

20080085885 - Inhibition of voluntary ethanol consumption with non-peptidyl melanocortin-4 receptor agonists: The present invention relates to methods of inhibiting or reducing voluntary alcohol consumption in a subject comprising administering a non-peptidyl melanocortin 4 receptor agonist to said subject. The present invention further relates to methods of treating or preventing alcoholism, alcohol abuse, and alcohol related disorders in a subject comprising administering... Agent: Merck And Co., Inc

20080085884 - Melanin concentrating hormone receptor-1 antagonist pyridinones: e

20080085887 - Pyrido [4,3-d] pyrimidin-4 (3h) -one derivatives as calcium receptor antagonists: wherein the variables R1, R2, R3, R4 and R5 are as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as... Agent: Pfizer Inc.

20080085888 - Therapeutic combinations: The present invention provides a combination of (a) an antipsychotic and (b) an alpha4/beta2 (α4β2)-neuronal nicotinic receptor agonist. The invention further relates to pharmaceutical compositions comprising said combination and to the use of the combination in therapy. The invention further relates to a kit comprising the combination and use of... Agent: Pepper Hamilton LLP

20080085889 - Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-n-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them: e

20080085890 - Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3 (2h)-isoquinolones and methods of use thereof:

20080085891 - Asthma and allergic inflammation modulators: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.... Agent: Jones Day

20080085892 - Liquid dosage form of acetaminophen: The present invention relates to a liquid dosage form comprising pharmaceutically insoluble and unpleasant active drug and liquid excipient base. In particular, the invention relates to a liquid dosage form comprising Acetaminophen and liquid excipient base as a solubilizer.... Agent: Jay R Akhave

20080085894 - Alpha-(n-sulfonamido)acetamide derivatives as beta-amyloid inhibitors: e

20080085893 - Matrix metalloprotease inhibitors:

20080085896 - Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications: The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to imidazo[1,2-a]pyridine containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or... Agent: Connolly Bove Lodge & Hutz LLP

20080085895 - Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds: Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R1)— group in the fused ring at the 1-position of the imidazo ring, wherein R1 includes a functional group, for example, an amide, sulfonamide, urea, carbamate, ester, ketone, ether, a thio analog of the forgoing, sulfone, oxime,... Agent: Wolf Greenfield & Sacks, P.c.

20080085897 - Use of 2-alkoxyphenyl-substituted imidazotriazinones: The present invention relates to the use of known 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position and cGMP PDE-inhibitory properties for the treatment of cardiac insufficiency, cancer, bladder disorders, or prostate hyperplasia.... Agent: Bayer Health Care Llc

20080085898 - 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression: The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula I:... Agent: Heslin Rothenberg Farley & Mesiti Pc

20080085899 - Tetrahydrothiopyrano pyrazole cannabinoid modulators: e

20080085900 - Sulfonylguanidine compounds and pharmaceutical uses thereof: Sulfonylguanidine compounds corresponding to the tautomeric formulas I and Ia, a method for producing them, pharmaceutical compositions containing them, and methods of using them to prepare medicaments and for treating various medical conditions. The sulfonylguanidine compounds have an affinity for the gabapentin binding site and can be used to treat... Agent: Crowell & Moring LLP Intellectual Property Group

20080085901 - Heteroaryl substituted quinolin-4-ylamine analogues: Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat... Agent: Edward Angell Palmer & Dodge, LLP Client: Neurogen Corporation

20080085902 - Combination of a vegf receptor inhibitor or with a chemotherapeutic agent: The present invention relates to a combination therapy for treating patients suffering from proliferative diseases or diseases associated with persistent angiogenesis. The patient is treated with a VEGF inhibitor compound; and one or more chemotherapeutic agents.... Agent: Novartis Corporate Intellectual Property

20080085903 - Novel crystalline forms of aripiprazole: The present invention provides novel crystalline forms of aripiprazole and aripiprazole hydrochloride, processes for their preparation and pharmaceutical compositions containing them.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20080085904 - 1,5-diphenylpyrazoles: Novel 1,5 diphenylpyrazole derivatives of the formula (I), in which R1-R6 have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.... Agent: Millen, White, Zelano & Branigan, P.c.

20080085905 - Pyrazine-2-carboxamide derivatives: v

20080085906 - 3-pyridinecarboxamide derivatives as hdl-cholesterol raising agents:

20080085907 - Hiv inhibiting bicyclic pyrimdine derivatives: HIV replication inhibitors of formula (1) N-oxides, pharmaceutically acceptable addition salts, quaternary amines or stereoisomeric forms thereof, wherein -a1=a2-a3=a4- is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; -b1=b2-b3=b4- is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; n and m is 0, 1, 2, 3 and in certain cases also 4; R1 is hydrogen; aryl;... Agent: Philip S. Johnson Johnson & Johnson

20080085908 - A2b adenosine receptor antagonists: Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.... Agent: Cv Therapeutics, Inc.

20080085909 - Purinones and 1h-imidazopyridinones as pkc-theta inhibitors: s

20080085910 - Glycine derivative and use thereof: A glycine derivative which is, e.g., the following compound (Chemical formula (1)). It is highly effective in the treatment and prevention of inflammatory bowel diseases. Compared to conventional compounds, the compound is excellent in absorbability in oral administration and in vivo stability. The compound can be orally administered and can... Agent: Ip Group Of Dla Piper Us LLP

20080085911 - Statin and omega-3 fatty acids for reduction of apo-b levels: Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease,... Agent: Arent Fox LLP

20080085912 - Isoxazole derivatives and methods of treating diseases: A series of isoxazole derivatives and methods of treating immune-mediated diseases by isoxazole derivatives are described.... Agent: Butzel Long

20080085913 - Polymorphic forms of a gabaa agonist: The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes... Agent: Darby & Darby P.c.

20080085914 - Use of organic compounds: e

20080085915 - Compounds and methods for the treatment of gastrointestinal and central nervous system disorders: wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080085916 - Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators: A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in... Agent: Alston & Bird LLP

20080085917 - 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyrid-1-yl)ethyl)isoquinoline besylate salt, preparation and therapeutic use thereof: The present invention relates to the besylate salt of 7-(2-(4-(3-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyrid-1-yl)ethyl)isoquinoline, to its preparation and to its use in therapeutics. The salt may be represented by the formula (II) below:... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080085918 - Fitness assay and associated methods: The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method... Agent: Leydig, Voit & Mayer, Ltd.

20080085919 - 1h-pyrazoles useful in therapy: or a pharmaceutically acceptable derivative thereof, wherein R1 and R3 independently represent H, C1-6alkyl, C3-8cycloalkyl, or halogen; R2 represents C1-6alkyl, CF3 or aryl; a represents 1 or 2; R4, R5, R7 and R8 independently represent H, C1-6alkyl, C1-6alkyloxy, CN or halogen, or R4 and R5, or R7 and R8, together... Agent: Pfizer Inc.

20080085920 - Compositions comprising nb-dnj, ne-dnj or d-glucaro-delta-lactam and their uses for the treatment of pain and other neurological condittions: Methods and compositions for the treatment of conditions including stress-associated, chronic pain, and neurodegenerative conditions in a mammal using a composition comprising NB-DNJ or a compound structurally similar thereto.... Agent: Allergan, Inc.

20080085921 - Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders: wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080085922 - Methods and ophthalmic devices used in the treatment of ocular allergies: Ophthalmic devices and methods of treating allergic conjunctivitis are disclosed herein.... Agent: Philip S. Johnson Johnson & Johnson

20080085923 - Thrombin receptor antagonists based on the modified tricyclic unit of himbacine: or a pharmaceutically acceptable salt, solvate, or ester of said compound wherein R and the stereochemistry are illustrated in the structural formulas herein are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080085924 - Biphenylcaboxamides:

20080085925 - Sulfonyltetrahydro-3h-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of a CNS disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20080085926 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... Agent: Merck And Co., Inc

20080085927 - 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.... Agent: Philip S. Johnson Johnson & Johnson

20080085928 - Sulfonamide derivatives: e

20080085929 - Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-β-cyclodextrin or sulfobutylether-7-β-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or... Agent: Heslin Rothenberg Farley & Mesiti Pc

20080085930 - Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate: The present invention relates to a novel crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate, pharmaceutical compositions comprising this crystal and, and methods of making and using this crystal.... Agent: Philip S. Johnson Johnson & Johnson

20080085931 - Method for inhibiting cancer using arsenic trioxide: The invention provides a method for treating cancers that are dependent on cyclin D1 for proliferation, survival, metastasis and differentiation, involving administering a composition containing an effective amount of arsenic trioxide to an affected patient. The arsenic trioxide can be administered orally, for example, as a solution, suspension, syrup, emulsion,... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080085932 - Pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease: The invention provides methods for treating beta-Amyloid protein-induced disease, pharmaceutical compositions and compounds useful for the same, and the use of these compounds for the manufacture of a medicament for treating the same. More particularly, the invention relates to the use of natural product compounds isolated from turmeric, gingko biloba,... Agent: Marshall, Gerstein & Borun LLP

20080085933 - Aqueous compositions containing monoester salts: Clear aqueous compositions comprising water, a hydrophobic organic compound, and from about 2 to about 50 wt. % of a solubilizer are disclosed. The solubilizer is an alkali metal or alkaline earth metal salt of a monoester of a saturated C6-C20 alcohol and a saturated dicarboxylic acid. The monoester salts... Agent: Lyondellbasell Industries

20080085934 - Bisdithiocarbamate fungicide stabilization: A composition comprising at least one bisdithiocarbamate fungicide and at least one zinc additive is provided. Processes related thereto are also provided.... Agent: Dow Agrosciences Llc

20080085935 - Bisdithiocarbamate fungicide stabilizers: A composition comprising at least one bisdithiocarbamate fungicide and at least one zinc additive is provided. Processes related thereto are also provided.... Agent: Dow Agrosciences Llc

20080085936 - Vanilloid trpv1 receptor antagonists: The invention relates to compounds of formula (I), wherein R, R1, R2, X and n are as defined in the description, and their use for the preparation of pharmaceutical compositions for the treatment of inflammatory states.... Agent: Ostrolenk Faber Gerb & Soffen

20080085937 - N-(2-hydroxyalkanoyl)-n,n'-dialkylureas and a process for their preparation: e

20080085938 - Arylamino-arylpropanolamine derivatives and methods of their use: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly... Agent: Wyeth Patent Law Group

20080085939 - Use of sphingolipids for prevention and treatment of atherosclerosis: The present invention is in the field of prevention and treatment of atherosclerosis and atherosclerosis-related clinical conditions. In particular, the present invention relates to the use of sphingolipids, more preferably phytosphingosine, sphingosine, sphinganine, ceramide, cerebroside lyso-sphingomyelin and/or sphingomyelin for prevention and treatment of inflammatory processes associated with atherosclerosis, psoriasis, colitis... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20080085940 - Method and device for non-destructive analysis of perforations in a material: Method for fabricating and inspecting small holes in a material are disclosed. The method includes directing light onto the material and through the holes formed in the material, and then collecting the light passing through the holes in the material onto a detector. The methods further include analyzing the light... Agent: Bozicevic, Field & Francis LLP

20080081782 - Method for the selective enrichment and labeling of phosphorproteins: The embodiments of the invention relate to a method for the introduction of a labeling structure such as a fluorescent molecules or a Raman tags to a compound. Imidazole functionalized resins or polymers are used to selectively immobilize phosphocompounds without protecting the carboxylic groups. Relying on the pKa difference between... Agent: Intel Corporation C/o Darby & Darby P.C.

20080081790 - Azithromycin for the treatment of nodular acne: Azithromycin, administered systemically, is an effective treatment for nodules associated with acne vulgaris.... Agent: Howard Eisenberg, Esq.

20080081792 - Methods and compositions for inhibiting the function of polynucleotide sequences: A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080081791 - Methods of using combinations of sirnas for treating a disease or a disorder, and for enhancing sirna efficacy in rnai: The present invention provides methods for treating diseases or disorders, and methods for enhancing siRNA efficacy in RNAi, including administering to a subject or a biological system one or more siRNAs capable of down regulating the expression of one or more target genes and one or more siRNAs capable of... Agent: Fish & Richardson PC

20080081793 - Oligonucleotide compositions and their use to induce apoptosis: The present invention provides novel synthetic oligonucleotide sequences (hereinafter sequence) of 3 to 9 bases in length comprising one or more non-DNA bases wherein the bases are nebularine, hypoxanthine, or uracil, or combinations of nebularine, hypoxanthine and uracil bases. These sequences optionally further comprise one or more guanine bases or... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080081797 - Topical formulations for the prevention of sexually transmitted disease and methods of producing the same: The present invention is directed towards various topical protective formulations which may be used as an adjunct in preventing the spread of a broad range of sexually transmitted diseases and the method by which it is produced. The product is intended to be used as a topical lotion, cream, emulsion,... Agent: Mchale & Slavin, P.A.

20080081780 - Identification of oligoadenylate synthetase-like genes: The present invention relates to compositions and methods for modulating conception in animals. More particularly, the composition modulates mRNA degradation during gametogenesis and early development. Yet further, the present invention relates to pharmaceutical compositions and methods for modulating diseases of the reproductive organs, such as hyperproliferative diseases.... Agent: Fulbright & Jaworski, LLP

20080081781 - Methods and compositions for the treatment of metabolic syndrome: Methods and compositions containing a berberine compound or berberine related or proto-berberine or derivative compound are provided for the prevention and treatment of metabolic and cardiovascular disorders including metabolic syndrome, hyperlipidemia, obesity, diabetes, insulin resistance, hyperglycemia, hypertension and elevated cholesterol in mammalian subjects. The methods and compositions of the invention... Agent: Black Lowe & Graham PLLC

20080081786 - Cytokine protein family: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral... Agent: Zymogenetics, Inc. Intellectual Property Department

20080081783 - Erythropoietin receptor peptide formulations and uses: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages... Agent: Darby & Darby P.C.

20080081787 - Medical compositions containing ghrelin: It is provided a pharmaceutical composition stably containing ghrelin or its derivative, which is an endogenous growth hormone secretagogue (GHS) to a growth hormone secretagogue-receptor (GHS-R), comprising a aqueous solution containing the ghrelins having pH range of 2 to 7, wherein the aqueous solution having pH range of 2 to... Agent: Hunton & Williams LLP

20080081784 - Paralytic peptide for use in neuromuscular therapy: The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.... Agent: Synnestvedt & Lechner, LLP

20080081785 - Paralytic peptide for use in neuromuscular therapy: The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxillary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.... Agent: Synnestvedt & Lechner, LLP

20080081788 - Diagnosis and treatment for immunoglobulin e (ige) implicated disorders: Human saliva is used as a non-invasive source instead of invasive blood serum plasma for detection and assay of endogenously present proteins; nerve growth factor (NGF), myoglobin, Insulin, adenosine deaminase (ADA), including immunoglobulin E (IgE). It was discovered that people having high levels of IgE, show high levels in comparison... Agent: John R. Casperson

20080081789 - Beta peptoids with antimicrobial activity: The present invention relates to beta-peptoids with antimicrobial activity. The present invention also relates to methods of producing β-peptoids. The antimicrobial β-peptoids of the invention are useful in pharmaceutical, healthcare, medical device, industrial, food, agricultural, and personal care applications.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080081794 - Smg-1 binding protein and screening method for substances that can regulate the activity thereof: A novel polypeptide binding to SMG-1, a polynucleotide encoding the same, and a system for screening a substance which artificially modifies an MRNA surveillance mechanism, are disclosed. The polypeptide has an activity of binding to SMG-1, an activity of being phosphorylated by SMG-1, and an activity of modifying SMG-1 activities... Agent: Heslin Rothenberg Farley & Mesiti PC

20080081795 - Suppression of nuclear factor-kappab dependent processes using oligonucleotides: Antisense oligonucleotides which hybridize with nuclear factor-κB (NF-κB) mRNA and methods of using these oligonucleotides.... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20080081796 - Treatment of mucositis: Disclosed are compositions and methods for alleviating mucositis, wherein said methods and compositions are directed to the formulation or use of selected nucleoside derivatives, especially ADP-ribose, that conform to the general formula A-B-X and pharmaceutically acceptable salts thereof, wherein “A” is a nucleoside structure selected from adenosine, guanosine, and uridine;... Agent: Porter Wright Morris & Arthur, LLP Intellectual Property Group

20080081798 - Pharmaceutical combinations for the treatment of head-aches and migraine attacks as well as blisters and packs that contain them: s

20080081800 - 2-methylene-(20r,25s)-19,27-dinor-(22e)-vitamin d analogs: This invention discloses 2-methylene-(20R,25S)-19,27-dinor-(22E)-vitamin D analogs, and specifically 2-methylene-(20R,25S)-19,27-dinor-(22E)-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis... Agent: Andrus, Sceales, Starke & Sawall, LLP

20080081799 - 2-methylene-(20s,25s)-19,27-dinor-(22e)-vitamin d analogs: This invention discloses 2-methylene-(20S,25S)-19,27-dinor-(22E)-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,27-dinor-(22E)-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis... Agent: Andrus, Sceales, Starke & Sawall, LLP

20080081801 - Porphyrin oxygen infusion for increasing concentrations in tumor tissues: A highly safe oxygen infusion for effectively increasing an oxygen partial pressure in a hypoxic region of tumor tissues, which comprises a dispersion of an albumin clathrate compound enclosing a porphyrin metal complex, dispersed in a physiologically permissible aqueous media.... Agent: Birch Stewart Kolasch & Birch

20080081802 - Thiazolyl-dihydro-indazole: h

20080081803 - Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity:

20080081804 - Combination of sabcomeline with a neuroleptic agent to treat psychotic disorders: The invention relates to adjunctive and simultaneous combination therapies for the treatment of psychotic disorders in which sabcomeline or a pharmaceutically acceptable salt thereof and at least one other neuroleptic agent are administered adjunctively or simultaneously. The invention provides methods of treatment of psychotic disorders utilising such adjunctive or simultaneous... Agent: Nixon & Vanderhye, PC

20080081806 - Treatment for parkinson's disease-combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor: The treatment regime is based upon the discovery that the primary cause of PD and various other related neurological conditions is dysfunction in the serotonergic pathways involving the brainstem, nucleus of Raphe, and various projecting serotonergic fibers. It has been determined that this dysfunction can be overcome by increasing the... Agent: Jerry M. Held

20080081807 - Arylphenyl-substituted cyclic keto-enols: A, B, D, G and Q1 to Q6 are each as defined in the description, to a plurality of processes for their preparation and to their use as pesticides and herbicides.... Agent: Bayer Cropscience Lp

20080081808 - Azaindole inhibitors of aurora kinases:

20080081809 - Novel compounds:

20080081810 - Oxindole derivatives:

20080081811 - Selective inhibitors against cdk4 and cdk6 having aminothiazole skeleton: R4 is a hydrogen atom, a lower alkyl group, a C3-C6 cycloalkyl group or the like, or a pharmaceutically acceptable salt or ester thereof, and a selective inhibitor against Cdk4 and/or Cdk6 or an anticancer agent containing the compound or a pharmaceutically acceptable salt or ester thereof.... Agent: Merck And Co., Inc

20080081812 - Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists: A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing the inventive heteroaryl-pyrasole compounds or a... Agent: Sughrue Mion, PLLC

20080081814 - Carbonyl compounds which can be used as inhibitors of coagulation factor xa: Novel compounds of the formula (I), in which D, E, G, W, X, Y, T, R1 and R2 have the meaning indicated in Patent Claim (1), are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20080081813 - Lipid lowering biphenylcarboxamides: v

20080081815 - Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists: A novel heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provide a method for preparing same, a pharmaceutical composition containing same,... Agent: Anderson, Kill & Olick, P.C.

20080081816 - Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3: An anti-inflammation substrate for decreasing the proinflammation induced by the cytokines and inhibiting the lung function degeneration is provided. The anti-inflammation substrate includes one selected from the group consisting of a 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine, a 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine, a respective pharmaceutical acceptable salt thereof, and a combination thereof.... Agent: Volpe And Koenig, P.C.

20080081817 - Nitrogenous fused bicyclic compound: A novel nitrogenous fused bicyclic compound represented by the following general formula [1] or a pharmacologically acceptable salt of the compound. They have excellent SK channel blocking activity and are useful as a medicine. [I] (In the formula, R0 represents hydrogen, halogeno, etc.; R1 represents a group represented by the... Agent: Birch Stewart Kolasch & Birch

20080081818 - New piperazine compound and use thereof as a hcv polymerase inhibitor: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful... Agent: Leydig Voit & Mayer, Ltd

20080081820 - Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one derivatives: R4 represents a hydrogen atom, a C1-4 alkoxy carbonyl group, a C1-5 alkyl group optionally substituted; o and m represent 1 to 2; n represents 0 to 3; p represents 0 to 2; and q represents 0 to 2. The invention relates also to a medicament comprising the said derivative... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080081819 - Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a] pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a] pyrimidin-6-one derivatives: wherein X, Y, R1, R2, R3, m, n, p and q are as described herein. Specifically, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080081821 - Aza-benzothiophenyl compounds and methods of use: The invention relates to azabenzothiophenyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzothiophenyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal.... Agent: Genentech, Inc.

20080081822 - Compounds which modulate the cb2 receptor: e

20080081823 - Pipecolic acid-containing antidiabetic compositions: The present invention discloses a composition containing a component that is an in vivo intrinsic substance and widely-consumed. The present invention provides a composition containing pipecolic acid in its provided amount of 20 mg/kg to 2000 mg/kg of body weight per day. The composition of the present invention can be... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080081824 - Substituted piperidines as modulators of chemokine receptor activity: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, n, Q1, R1, R2, R3, R4, R5, R6, R7, T1, T2, W1, W2, W3 and Z1 are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune... Agent: Louis J. Wille Bristol-myers Squibb Company

20080081825 - Nitrogen-containing heterocyclic compounds and medicinal use thereof: wherein each symbol is as defined in the description, salts thereof, N-oxides thereof, solvates thereof, or prodrugs thereof are useful in preventing and/or treating diseases that are supposedly caused or deteriorated by abnormal production of cytokines including inflammatory cytokines or chemokines, or by overresponse thereto, namely cytokine-mediated diseases such as... Agent: Sughrue-265550

20080081826 - System for effecting weight loss: The present invention relates to a method for effecting or maintaining weight loss in an individual in need thereof. The method includes the administration of a weight loss agent in conjunction with a meal replacement formulation. The weight loss agent can be administered separately or co-formulated with the meal replacement... Agent: Robert Deberardine Abbott Laboratories

20080081827 - Use of a pyrazole-derived compound that is an antagonist for cannabinoid cb1 receptors, for treating or preventing chronic bronchitis or chronic obstructive bronchopneumopathy: The present invention relates to a method for treating or preventing chronic bronchitis and chronic obstructive pulmonary disease, and also the chronic bronchitis associated with chronic pulmonary disease in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the pyrazole-derived compound that is an... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080081828 - Agent for curing chronic obstructive pulmonary disease: e

20080081829 - Medical device including an anesthetic and method of preparation thereof: Non-metallic implantable medical devices including an anesthetic having a proton binding site with a non-ionic form and an ionic form. At least 5% w/w of the anesthetic is present with the proton binding site in the non-ionic form and the remainder of the anesthetic is present with the proton binding... Agent: Brinks Hofer Gilson & Lione/chicago/cook

20080081830 - Method of treating tremors: The invention is directed to the use of a pharmaceutical composition comprising an effective amount of zonisamide or a pharmaceutically acceptable salt thereof to treat tremors, such as rest tremors or action tremors. Tremors may include kinetic tremor, essential tremor, severe essential tremor, postural tremor, drug-induced tremor, toxic tremor, primary... Agent: Venable LLP

20080081831 - Peptidomimetic modulators of cell adhesion: Peptidomimetics of cyclic peptides, and compositions comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a... Agent: Seed Intellectual Property Law Group PLLC

20080081832 - Imidazole derivatives, processes for preparing them and their uses: The present invention relates to imidazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Morgan Lewis & Bockius LLP

20080081833 - Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors: e

20080081834 - Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders: Methods and compositions are provided for formulating and administering bicifadine and related compounds to treat or prevent functional impairment and disabilities associated with acute pain, chronic pain, and neuropathic disorders.... Agent: Black Lowe & Graham PLLC

20080081835 - Use of ltb4 inhibitors for the treatment of b-cell leukemias and lymphomas: The invention relates to the use of an inhibitor of the biosynthesis and/or function of LTB4 for the manufacture of a medicament for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), B-prolymphocytic leukemia (B-PLL) or B-cell lymphoma. Preferably, the inhibitor of the biosynthesis and/or function of LTB4 is the inhibitor... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080081836 - Anti-tuberculosis taxane compounds: The present invention relates to compounds having the formula (I):... Agent: Hoffmann & Baron, LLP

20080081837 - Use of furan alkyl for preparing an antidiabetic drug: The invention relates to using one or several synthetic or natural furan alkyls for preparing a drug for preventing and/or treating diabetes and insulin resistance, thereby preventing the risks of cardiovascular, nervous, cutaneous, renal, ocular and infectious diseases. The use of one or several synthetic or natural furan alkyls for... Agent: Foley And Lardner LLP Suite 500

20080081838 - Inhibition of tnf-alpha-initiated neutrophil response: The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNFα)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically stable LX analogs. At concentrations as low as 1-10 nM, the LXA4 and ATL analogs each inhibited TNFα-stimulated superoxide anion generation and IL-1β release... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080081839 - Compounds useful for treating neurological disorders: The invention relates to the use of compounds for the preparation of a medicament for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. The invention additionally relates to a pharmaceutical composition comprising compounds for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. A method for treating neuropathic pain,... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080081840 - Meal replacement compositions and weight control method: A food composition having a high protein level and comprising DHA, preferably for use as a meal replacement, is administered to subjects in order to control their weight.... Agent: Sheldon Mak Rose & Anderson PC

20080081841 - Materials and methods for modulating cell motility: The invention is based on CGI-27 (named Memo for mediator of ErbB2-dependent cell motility) and its role in cell motility. The invention provides methods of inhibiting cell migration, particularly late phase cell migration e.g. which is induced by signals from the EGF-R. Also provided a related methods and materials for... Agent: Novartis Corporate Intellectual Property